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A B S T R A C T
Background
Plasmodium vivax liver stages (hypnozoites) may cause relapses, prolonging morbidity, and impeding malaria control and elimination.
The World Health Organization (WHO) recommends three schedules for primaquine: 0.25 mg/kg/day (standard), or 0.5 mg/kg/day (high
standard) for 14 days, or 0.75 mg/kg once weekly for eight weeks, all of which can be diEicult to complete. Since primaquine can cause
haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, clinicians may be reluctant to prescribe primaquine
without G6PD testing, and recommendations when G6PD status is unknown must be based on an assessment of the risks and benefits of
prescribing primaquine. Alternative safe and eEicacious regimens are needed.
Objectives
To assess the eEicacy and safety of alternative primaquine regimens for radical cure of P vivax malaria compared to the standard or high-
standard 14-day courses.
Search methods
We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL);
MEDLINE (PubMed); Embase (Ovid); LILACS (BIREME); WHO International Clinical Trials Registry Platform and ClinicalTrials.gov up to 2
September 2019, and checked the reference lists of all identified studies.
Selection criteria
Randomized controlled trials (RCTs) of adults and children with P vivax malaria using either chloroquine or artemisinin-based combination
therapy plus primaquine at a total adult dose of at least 210 mg, compared with the WHO-recommended regimens of 0.25 or 0.5 mg/kg/
day for 14 days.
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Data collection and analysis
Two review authors independently assessed trial eligibility and quality, and extracted data. We calculated risk ratios (RRs) with 95%
confidence intervals (CIs) for dichotomous data. We grouped eEicacy data according to length of follow-up, partner drug, and trial location.
We analysed safety data where included.
Main results
0.5 mg/kg/day for seven days versus standard 0.25 mg/kg/day for 14 days
There may be little or no diEerence in P vivax recurrences at six to seven months when using the same total dose (210 mg adult dose) over
seven days compared to 14 days (RR 0.96, 95% CI 0.66 to 1.39; 4 RCTs, 1211 participants; low-certainty evidence). No serious adverse events
were reported. We do not know if there is any diEerence in the number of adverse events resulting in discontinuation of primaquine (RR
1.04, 95% CI 0.15 to 7.38; 5 RCTs, 1427 participants) or in the frequency of anaemia (RR 3.00, 95% CI 0.12 to 72.91, 1 RCT, 240 participants)
between the shorter and longer regimens (very low-certainty evidence). Three trials excluded people with G6PD deficiency; two did not
provide this information. Pregnant and lactating women were either excluded or no details were provided.
High-standard 0.5 mg/kg/day for 14 days versus standard 0.25 mg/kg/day for 14 days
There may be little or no diEerence in P vivax recurrences at six months with 0.5 mg/kg/day primaquine for 14 days compared to 0.25 mg/
kg/day for 14 days (RR 0.84 (95% CI 0.49 to 1.43; 2 RCTs, 677 participants, low-certainty evidence). No serious adverse events were reported.
We do not know whether there is a diEerence in adverse events resulting in discontinuation of treatment with the high-standard dosage
(RR 4.19, 95% CI 0.90 to 19.60; 1 RCT, 778 participants, very low-certainty evidence). People with G6PD deficiency and pregnant or lactating
women were excluded.
0.75 mg/kg/week for eight weeks versus high-standard 0.5 mg/kg/day for 14 days
We do not know whether weekly primaquine increases or decreases recurrences of P vivax compared to high-standard 0.5 mg/kg/day for
14 days, at 11 months' follow-up (RR 3.18, 95% CI 0.37 to 27.60; 1 RCT, 122 participants; very low-certainty evidence). No serious adverse
events and no episodes of anaemia were reported. G6PD-deficient patients were not randomized but included in the weekly primaquine
group (only one patient detected).
1 mg/kg/day for seven days versus high standard 0.5 mg/kg/day for 14 days
There is probably little or no diEerence in P vivax recurrences at 12 months between 1.0 mg/kg/day primaquine for seven days and the
high-standard 0.5 mg/kg/day for 14 days (RR 1.03, 95% CI 0.82 to 1.30; 2 RCTs, 2526 participants; moderate-certainty evidence). There may
be moderate to large increase in serious adverse events in the 1.0 mg/kg/day primaquine for seven days compared with the high-standard
0.5 mg/kg/day for 14 days, during 42 days follow-up (RR 12.03, 95% CI 1.57 to 92.30; 1 RCT, 1872 participants, low-certainty evidence). We
do not know if there is a diEerence between 1.0 mg/kg/day primaquine for seven days and high-standard 0.5 mg/kg/day for 14 days in
adverse events that resulted in discontinuation of treatment (RR 2.50, 95% CI 0.49 to 12.87; 1 RCT, 2526 participants, very low-certainty
evidence), nor if there is diEerence in frequency of anaemia by 42 days (RR 0.93, 95% CI 0.62 to 1.41; 2 RCTs, 2440 participants, very low-
certainty evidence). People with G6PD deficiency were excluded.
Other regimens
Two RCTs evaluated other rarely-used doses of primaquine, one of which had very high loss to follow-up. Adverse events were not reported.
People with G6PD deficiency and pregnant or lactating women were excluded.
Authors' conclusions
Trials available to date do not detect a diEerence in recurrence between the following regimens: 1) 0.5 mg/kg/day for seven days versus
standard 0.25 mg/kg/day for 14 days; 2) high-standard 0.5 mg/kg/day for 14 days versus standard 0.25 mg/kg/day for 14 days; 3) 0.75 mg/
kg/week for eight weeks versus high-standard 0.5 mg/kg/day for 14 days; 4) 1 mg/kg/day for seven days versus high-standard 0.5 mg/kg/
day for 14 days. There were no diEerences detected in adverse events for Comparisons 1, 2 or 3, but there may be more serious adverse
events with the high seven-day course in Comparison 4.
The shorter regimen of 0.5 mg/kg/day for seven days versus standard 0.25 mg/kg/day for 14 days may suit G6PD-normal patients. Further
research will help increase the certainty of the findings and applicability in diEerent settings.
P L A I N   L A N G U A G E   S U M M A R Y
Primaquine to cure people with Plasmodium vivax malaria: comparing dosing schedules
Plasmodium vivax malaria can sometimes cause potentially life-threatening illness, and the infection continues to make many people
unwell. The infection includes a liver stage, and this requires primaquine to eradicate it and prevent the infection recurring. However, the
current dosing schedule requires 14 days of daily treatment.
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What are the concerns about primaquine?
Primaquine is the only drug currently recommended to treat the liver parasites in P vivax malaria. It can cause anaemia in people with
glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is a relatively common genetic blood disorder. Shorter regimens would help
reduce the risk of default with the current two-week regimen.
What does the research say?
We summarized trials that compared the World Health Organization (WHO)-recommended primaquine regimen of 15 mg to 30 mg per day
for 14 days with the same (210 mg) or higher total doses of primaquine given over diEerent lengths of time to determine whether alternative
regimens were as successful as the recommended courses at preventing future episodes of P vivax malaria. We searched for trials up to
2 September 2019 and included 11 randomized controlled trials (RCTs) (studies in which participants are assigned to one of two or more
treatment groups in a random manner) in our analysis.
When using 30 mg primaquine per day for seven days compared to 15 mg per day for 14 days, there may be little or no diEerence in P
vivax recurrences at six to seven months (low-certainty evidence). No serious adverse events were reported. We do not know if there is a
diEerence in the number of adverse events that cause people to stop taking the drug (low-certainty evidence).
When using 30 mg per day compared to 15 mg per day primaquine therapy for 14 days, we do not know if there is any diEerence in P vivax
recurrences at six months (very low-certainty evidence). No serious adverse events were reported, but it is unclear whether or not there is
a diEerence between doses in other adverse events that cause people to stop taking the drug (very low-certainty evidence).
We do not know whether primaquine at 45 mg once per week for eight weeks increases or decreases recurrences of P vivax compared to
the high standard 30 mg per day for 14-days, at 11 months' follow-up (very low-certainty evidence).
There is probably little or no diEerence for recurrence using high dose 60 mg per day for seven days compared to the high standard 30 mg
per day for 14 days, but there may be an increase in serious adverse events in the high-dose shorter course regimen group.
Further RCTs will help improve the certainty of the evidence around alternative regimens,
How up-to-date is this review?
The review authors searched for studies up to 2 September 2019.
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Summary of findings 1.   Summary of findings table 1 (main comparison)
0.5 mg/kg primaquine/day for 7 days versus standard 0.25 mg/kg/day for 14 days for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: India, Peru, Brazil
Intervention: 0.5 mg/kg/day primaquine for 7 days (adult dose 30 mg/day, total dose 210 mg)
Comparison: standard 14-day course primaquine (0.25 mg/kg/day, adult dose 15 mg/day; total dose 210 mg)
Anticipated absolute effects* (95% CI)Outcomes
Risk with stan-
dard 14-day
course pri-
maquine
Risk with 0.5mg/kg/
day primaquine for
7 days
Relative
effect
(95% CI)
№ of
partici-
pants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Recurrence of P vivax
parasitaemia
Follow-up: range 6
months to 7 months
84 per 1000 81 per 1000
(55 to 117)
RR 0.96
(0.66 to
1.39)
1211
(4 RCTs)
⊕⊕⊝⊝
LOWa,b
due to risk of bias and
imprecision
There may be little or no difference be-
tween 0.5 mg/kg/day primaquine for 7 days
and the standard 14-day course.
Serious adverse events Not estimable (0
events in 723 par-
ticipants)
Not estimable (0
events in 704 partici-
pants)
Not es-
timable
1427
(5 RCTs)
— No events reported.
Adverse events that re-
sult in the discontinua-
tion of treatment
3 per 1000 3 per 1000
(0 to 20)
RR 1.04
(0.15 to
7.38)
1427
(5 RCTs)
⊕⊝⊝⊝
VERY LOWc,d
due to risk of bias and
serious imprecision
We do not know if there is any difference in
adverse events that result in treatment dis-
continuation between 0.5 mg/kg/day pri-
maquine for 7 days and the standard 14-day
course.
Anaemia or change in
haemoglobin status
Not estimable (0
events in 120 par-
ticipants)
Not estimable (1
event in 120 partici-
pants)
RR 3.0
(0.12 to
72.91)
240
(1 RCT)
⊕⊝⊝⊝
VERY LOWe,f,g
due to risk of bias, indi-
rectness, and serious im-
precision
We do not know if the occurrence of
anaemia differs between the 2 treatment
regimens.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
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GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once for risk of bias: Rajgor 2014 IND, which contributed the most weight to the meta-analysis, was at high risk of selection bias due to no allocation concealment
and high risk of attrition bias. Although Pareek 2015 IND was at risk of selection bias as well as other bias for being funded and carried out by drug company, it only contributed
a small amount of weight to the meta-analysis.
bDowngraded once for imprecision: wide CIs - may be 34% reduction in malaria recurrences or 40% increase with 0.5 mg/kg/day primaquine for seven days.
cDowngraded once for risk of bias: Rajgor 2014 IND was at high risk of selection bias due to no allocation concealment and high risk of attrition bias. Pareek 2015 IND was at risk
of selection bias as well as other bias for being funded and carried out by drug company.
dDowngraded twice for serious imprecision: very few events (only four events occurring in one trial, Rajgor 2014 IND), very wide CIs.
eDowngraded once due to risk of bias: Pareek 2015 IND was at risk of selection bias and other bias (funded and performed by drug company).
fDowngraded once for indirectness: only one study that excluded G6PD-deficient adults measured this safety outcome (Pareek 2015 IND).
gDowngraded twice for serious imprecision: only one event (in the 0.5 mg/kg/day primaquine for seven days group), very wide CIs.
 
 
Summary of findings 2.   Summary of findings table 2
High standard 0.5 mg/kg primaquine /day for 14 days versus standard 0.25 mg/kg/day for 14 days for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: India
Intervention: high-standard 14-day course primaquine (0.5 mg/kg/day, adult dose 30 mg/day; total dose 420 mg)
Comparison: standard 14-day course primaquine (0.25 mg/kg/day, adult dose 15 mg/day; total dose 210 mg)
Anticipated absolute effects* (95% CI)Outcomes
Risk with stan-
dard 14-day
course pri-
maquine
Risk with high-stan-
dard 14-day course
primaquine
Relative
effect
(95% CI)
№ of
partici-
pants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
Recurrence of P vivax
parasitaemia
follow-up: range 6
months to 7 months
82 per 1000 69 per 1000
(40 to 117)
RR 0.84
(0.49 to
1.43)
677
(2 RCTs)
⊕⊕⊝⊝
LOWa,b
due to risk of bias
and imprecision
There may be little or no difference in P vivax re-
currences between high-standard or standard
14-day courses of primaquine given with chloro-
quine or an ACT.
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Serious adverse events Not estimable (0
events in 398 par-
ticipants)
Not estimable (0
events in 380 partici-
pants)
Not es-
timable
778
(1 RCT)
— No events reported.
Adverse events that re-
sult in the discontinua-
tion of treatment
5 per 1000 21 per 1000
(5 to 98)
RR 4.19
(0.90 to
19.60)
778
(1 RCT)
⊕⊝⊝⊝
VERY LOWc,d,e
due to indirectness,
risk of bias, and im-
precision
We do not know if there is any difference in ad-
verse events resulting in treatment discontinua-
tion between high-standard or standard 14-day
courses of primaquine.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: ACT: artemisinin-based combination therapy; CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once for risk of bias: one study was open-label with no allocation concealment (risk of selection bias) and risk of attrition bias due to high percentage not completing
six months' follow-up with minimal explanation; the other study had no blinding and a high rate of loss to follow-up.
bDowngraded once for imprecision: wide CIs - range of 51% reduction in malaria recurrences at six months with high-standard 14-day course of primaquine to 43% increase in
number of malaria recurrences.
cDowngraded once for indirectness: only one trial that excluded G6PD-deficient adults measured this safety outcome (Rajgor 2014 IND).dDowngraded once for risk of bias: open-
label with no allocation concealment (risk of selection bias) and risk of attrition bias due to high percentage not completing six months' follow-up with minimal explanation.
eDowngraded once for imprecision: wide CIs 0.9 to 19.6 - range of 10% reduction in adverse events with high-standard 14-day course to 186% increase in adverse events.
 
 
Summary of findings 3.   Summary of findings table 3
0.75 mg/kg primaquine /week for 8 weeks versus high-standard 0.5 mg/kg/day for 14 days for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: Pakistan
Intervention: 0.75 mg/kg primaquine/week for 8 weeks (adult dose 45 mg/week; total dose 360 mg)
Comparison: high-standard 14-day course primaquine (0.5 mg/kg/day, adult dose 30 mg/day; total dose 420 mg)
Anticipated absolute effects* (95% CI)Outcomes
Risk with high-standard 14-
day course primaquine
Risk with once-weekly 0.75 mg/
kg primaquine for 8 weeks
Relative ef-
fect
(95% CI)
№ of
partici-
pants
(trials)
Certainty of
the evidence
(GRADE)
Comments
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Recurrence of P vi-
vax malaria
Follow-up: 11
months
19 per 1000 59 per 1000
(7 to 511)
RR 3.18
(0.37 to
27.60)
122
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b
due to risk of
bias and serious
imprecision
We do not know if weekly pri-
maquine reduces the risk of
malaria recurrences when com-
pared to the high-standard 14-
day course.
Serious adverse
events
Not estimable (0 events in 55
participants)
Not estimable (0 events in 74 par-
ticipants)
Not es-
timable
129
(1 RCT)
— No events reported.
Anaemia (haemo-
globin < 7 g/dL)
Not estimable (0 events in 55
participants)
Not estimable (0 events in 74 par-
ticipants)
Not es-
timable
129
(1 RCT)
— No events reported.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once for risk of bias: Leslie 2008 PAK was at high risk of bias for randomization process, allocation concealment, and incomplete outcome data.
bDowngraded twice for serious imprecision: few events, very wide CIs that incorporated a potential large beneficial eEect and a potential large harmful eEect.
 
 
Summary of findings 4.   Summary of findings table 4
1.0 mg/kg primaquine /day for 7 days versus high-standard 0.5 mg/kg/day for 14 days for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Settings: Afghanistan, Ethiopia, Indonesia, Thailand, and Vietnam
Intervention: 1.0 mg/kg/day primaquine for 7 days (adult dose 60 mg/day; total dose 420mg)
Comparison: high-standard 14-day course primaquine (0.5 mg/kg/day, adult dose 30 mg/day; total dose 420mg)
Anticipated absolute
effects* (95% CI)
Outcomes
Risk
with
Risk with
1.0 mg/kg/
Relative
effect
(95% CI)
№ of
Partici-
pants
(trials)
Certainty of the evi-
dence
(GRADE)
Comments
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high-
stan-
dard
14-day
course
pri-
maquine
day pri-
maquine
for 7 days
Recurrence of P vi-
vax parasitaemia
Follow-up: 12
months
104 per
1000
107 per 1000
(85 to 135)
RR 1.03
(0.82 to
1.30)
2526
(2 RCTs)
⊕⊕⊕⊝a
MODERATE
due to risk of bias
There is probably little or no difference between 1.0 mg/kg/day pri-
maquine for 7 days and the high-standard 0.5 mg/kg/day for 14 days
course
Serious adverse
events
Follow-up: up to 42
days
1 per
1000
13 per 1000
(2 to 99)
RR 12.03
(1.57 to
92.30)
1872
(1 RCT)
⊕⊕⊝⊝b,c
LOW
due to indirectness
and imprecision
There may be a moderate to large increase in serious adverse events
in the 1.0 mg/kg/day primaquine for 7 days compared with the high-
standard 0.5 mg/kg/day
Chu 2019 THA provides overall narrative results only, see Effects of in-
terventions text.
Adverse events the
resulted in discon-
tinuation of treat-
ment
2 per
1000
4 per 1000
(1 to 20)
RR 2.50
(0.49 to
12.87)
2526
(2 RCTs)
⊕⊝⊝⊝a,b,d
VERY LOW
due to risk of bias, in-
directness and serious
imprecision
We do not know if there is any difference in adverse events resulting in
treatment discontinuation between 1.0 mg/kg/day primaquine for 7
days and the high-standard 0.5 mg/kg/day for 14 days course.
Anaemia
Follow-up: be-
tween 3 and 42
days follow-up
35 per
1000
33 per 1000
(22 to 50)
RR 0.93
(0.62 to
1.41)
2440
(2 stud-
ies)
⊕⊝⊝⊝a,b,e
VERY LOW
due to risk of bias, in-
directness and impre-
cision
We do not know if there is any difference in anaemia between 1.0 mg/
kg/day primaquine for 7 days and the high-standard 0.5 mg/kg/day
for 14 days course.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; DHA-PPQ: dihydroartemisinin-piperaquine; RCT: randomized controlled trial; RR: Risk Ratio
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
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aDowngraded once for risk of bias: Chu 2019 THA was an open-label trial with high risk of performance and detection bias; although drop-outs were balanced between groups
the proportion of drop-outs aRer one year was high in both trials (30-40%).
bDowngraded once for indirectness: G6PD-deficient children and adults were excluded from the two trials that measured this outcome (Chu 2019 THA; Taylor 2019 MULTI).
cDowngraded once for imprecision: few events.
dDowngraded twice for imprecision: few events and a very wide 95% CI that incorporated a potential large beneficial eEect and a potential large harmful eEect.
eDowngraded once for imprecision: few events and a wide 95% CI that incorporated a potential moderate beneficial eEect and a potential moderate harmful eEect.
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B A C K G R O U N D
Malaria is a potentially life-threatening disease caused by the
Plasmodium parasite, which is transmitted by the bite of an
infected female Anopheles mosquito. Five species of Plasmodium
malaria parasites can cause malaria disease in humans, of which
Plasmodium vivax and Plasmodium falciparum are the most
important (WHO 2016). In 2018, an estimated 228 million cases of
malaria occurred worldwide and an estimated 405,000 people died
from the disease (WHO 2019). The World Health Organization (WHO)
aims to reduce malaria case load and mortality by at least 90% by
2030 (WHO 2016).
Historically, P vivax infection was thought to be a milder form of
malaria, and researchers have focused on P falciparum due to the
high number of deaths it causes (Bassat 2016). In recent years,
it has been shown that the morbidity and mortality of P vivax
have been underestimated, with evidence of direct fatality and
contribution to mortality in patients who have other comorbidities,
such as malnutrition, HIV, or coexisting infections (Baird 2013;
Bhattacharjee 2013; Rizvi 2013; Singh 2013; Battle 2014; Douglas
2014; Kochar 2014; Arévalo-Herrera 2015; Baird 2015b). Repeated
P vivax infections through childhood and adulthood also aEect
personal well-being, development, and education and can thus
negatively impact economic development, both for the individual
and the community (Mendis 2001). P vivax malaria in pregnancy
is associated with maternal anaemia, spontaneous abortion,
stillbirth, and low birthweight, with especially poor pregnancy
outcomes for women with severe infection (McGready 2012; Rijken
2012; Brutus 2013).
Description of the condition
P vivax infection caused an estimated 7.5 million cases of malaria in
2018 (WHO 2019). The geographical distribution of P vivax malaria
is more widespread than any of the other forms of human malaria,
with around 35% of the world’s population thought to be at risk
(Howes 2016). Co-infection with P falciparum is also common
in many regions (Kumar 2007; Mueller 2009). As malaria control
accelerates, the P vivax proportion in co-endemic areas tends to rise
compared to that of P falciparum, which highlights the importance
and challenge of this infection (John 2012).
P vivax is important because as many countries progress
towards malaria elimination, the parasite becomes a roadblock
to eradication (Cibulskis 2015; Bassat 2016). Despite a reported
45% reduction in P vivax malaria cases between 2010 and 2016
(WHO 2017), the parasite has several characteristics that enable it to
evade control (Newby 2016). The early appearance of gametocytes
in the blood, oRen prior to symptoms of malaria, increases the
chance of onward transmission by mosquitoes (Mendis 2001). P
vivax diEers from P falciparum in that as well as having a blood-
stage infection, hypnozoites develop in the liver that can be
dormant for weeks to months before developing into an infection
(White 2011). What triggers these relapses is not well-understood.
There is diEiculty in distinguishing between relapse (hypnozoite
activation), recrudescence (subpar treatment of the initial blood-
stage infection), and re-infection (new infection with P vivax)
(Imwong 2007). A study in Papua New Guinea suggested that
relapses cause four-fiRhs of P vivax infections (Robinson 2015),
reinforcing the importance of relapse in sustaining transmission
(White 2011). Parasites show high genetic diversity, even in
countries that are at malaria elimination stage (Koepfli 2015). P
vivax is likely underestimated worldwide, as the dormant liver stage
is not detected in routine surveys (Gething 2012). Submicroscopic
infections and asymptomatic infection reservoirs may also lead
to underdiagnosis or misdiagnosis. A systematic review showed
that across all study sites, the polymerase chain reaction (PCR)
prevalence of P vivax was significantly higher than that identified by
light microscopy (Cheng 2015). The eEect this may have on P vivax
malaria studies is unclear.
There are diEerent strains of P vivax according to geographical
region/endemicity areas, with relapse patterns that vary by latency
(time to first relapse), likelihood of relapse, and frequency of
relapses, which further complicates the assessment of eEicacy of
drugs on relapses (Battle 2014; White 2016). Strains commonly
found in Southeast Asia and Oceania (including the ‘Chesson’ strain
isolated from an individual infected in Papua New Guinea) have
the shortest latency time to relapse, starting as early as three
weeks aRer first infection (if untreated with a hypnozoiticidal drug)
(Ehrman 1945). These areas correspond to zones 10 and 12 in Battle
2014. Indian and Pakistan strains (zone 8) exhibit heterogeneity in
relapse latency, incidence, and frequency, while South American
strains (zone 3) have a pattern of short latency to first relapse
and less frequent relapses than in zones 10 and 12 (Battle 2014).
The temperate strains (which include those from Korea in zone 11)
relapse much more slowly (John 2012; Battle 2014). Strains of the
type in zones 10 and 12, referred to here as 'East Asia and Oceania',
are recommended to receive higher doses of primaquine (the high-
standard course of 0.5 mg/kg/day rather than standard 0.25 mg/kg/
day for 14 days) to prevent relapses (WHO 2015), apparently based
on research done in the 1950s and 1960s (Coatney 1953; Jones
1953; Vivona 1961; MaEi 1971; Clyde 1977), although not all these
studies were done with strains from the targeted geographic area.
Primaquine, an 8-aminoquinoline, has until very recently been
the only drug available on the market for treating the hypnozoite
stage of infection (Ashley 2014). One of the main barriers in
P vivax treatment is the reluctance to use primaquine due to
it potentially causing haemolysis in patients with glucose-6-
phosphate dehydrogenase (G6PD) deficiency. G6PD deficiency is
the most common enzyme deficiency worldwide and aEects red
blood cells by leading to their premature lysis (Nkhoma 2009).
G6PD deficiency is common in countries where P vivax malaria is
endemic, with an estimated population prevalence of 8% (Howes
2012). Within G6PD deficiency, there are diEering phenotypes,
meaning some people may be mildly sensitive to primaquine,
while others may be very sensitive and experience life-threatening
haemolysis (Baird 2015a), which explains the varying responses to
primaquine. In many areas where P vivax is predominant, testing
for G6PD deficiency is not available locally (Baird 2015b). In 2018
the US Food and Drug Administration (FDA) approved a newer
alternative, another 8-aminoquinoline known as tafenoquine (MMV
2018), which has shown promise in reducing relapses, but there
are increased safety concerns in patients with undiagnosed G6PD
deficiency compared to primaquine, due to its longer half-life
(Rajapakse 2015).
Description of the intervention
People with P vivax malaria require treatment with an antimalarial
drug to treat the blood-stage infection, and a drug to treat the
hypnozoite stage (radical cure). The WHO recommends treatment
with either chloroquine or an artemisinin-based combination
therapy (ACT) for the blood-stage infection, with 0.25 to 0.5 mg/
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kg/day primaquine for 14 days for the liver stages (WHO 2015).
Artemisinin-based combination therapies and chloroquine have
been shown to be eEective and comparable in treating the blood-
stage infection of P vivax malaria (Gogtay 2013).
A previous Cochrane Review showed that primaquine regimens of
five days or fewer had similar recurrence rates to placebo or no
primaquine. Of the comparisons included in the review, a regimen
of 0.25 mg/kg/day (15 mg) a day of primaquine for 14 days had the
lowest recurrence rates of P vivax infection (Galappaththy 2013).
There were no trials at that time that compared higher doses of
primaquine at 14 or 7 days.
Primaquine was first made available to North American soldiers
in the 1950s (Baird 2004). Its mechanism and metabolism are
not widely understood, but it has a broad spectrum of activity
against the Plasmodium parasite. As well as preventing relapse of
P vivax malaria by targeting the latent and developing hypnozoites
in the liver, it is also used in malaria prophylaxis (Baird 2003)
and is gametocytocidal (Graves 2018). It is absorbed from the
gastrointestinal tract, has a half-life of about four to nine hours, and
crosses the placenta in pregnancy (Baird 2004). New advancements
in studying P vivax in humanized mice may lead to a greater
understanding of the mechanism of action of the drug (Mikolajczak
2015).
Adverse events observed with primaquine include production
of methaemoglobin, an oxidated state of haemoglobin that
cannot transport oxygen to tissues. Methaemoglobinaemia (an
abnormal buildup of methaemoglobin) can result in cyanosis when
levels exceed 10% of the usual haemoglobin level (Vale 2009).
As described above, primaquine causes haemolysis in people
with G6PD deficiency, which leads to anaemia (Ashley 2014).
When taken on an empty stomach it can cause abdominal pain
and gastrointestinal upset (Vale 2009). Safe use of primaquine
during pregnancy has not been established. The radical cure with
primaquine can be delayed until aRer pregnancy. With regard
to breastfeeding patients, a recent study showed that the levels
of primaquine in breast milk may not be suEicient to cause
haemolysis even in a G6PD-deficient baby (Gilder 2018), but it is not
recommended at this time.
How the intervention might work
The WHO advises that 0.25 mg (standard) to 0.5 mg/kg/day (high
standard) of primaquine for 14 days (total dose 210 mg or 420
mg) should be used for radical cure of P vivax malaria in patients
over six months old, excluding people with G6PD deficiency and
those who are pregnant or breastfeeding (WHO 2015). Citing the
review previous Cochrane Review of this topic (Galappaththy
2013), the WHO notes that the standard regimen reduced relapses
during 15 months of follow-up by about 40% compared to placebo
or no primaquine (high-quality evidence), and reduced relapses
during six months follow-up by over 50% compared to seven
days primaquine (low-quality evidence) (WHO 2015). The increased
dosing in the high standard 0.5 mg/kg/day regimen was previously
recommended in East Asia and Oceania based on suggestion of
failure of the standard regimen of 0.25 mg/kg/day for 14 days for
strains of P vivax in these areas (including the Chesson strain).
The guidelines note that "no direct comparison has been made of
higher doses (0.5 mg/kg bw for 14 days) with the standard regimen
(0.25 mg/kg bw for 14 days)". Given that the 15 trials included in
the WHO assessment excluded G6PD-deficient persons (12 trials) or
did not comment on their exclusion, WHO guidelines also stated "in
the absence of evidence to recommend alternatives, the guidelines
development group consider 0.75 mg/kg bw primaquine given
once weekly for 8 weeks to be the safest regimen for people with
mild to moderate G6PD deficiency", but no trials of this regimen
were included in the WHO guidance (WHO 2015).
The 14-day course of primaquine at any dose, as well as the eight-
week course, can lead to treatment adherence issues, as well as
to safety concerns about haemolysis in places where G6PD testing
is not available, meaning that shorter courses of primaquine are
desirable. Failure to treat the hypnozoite stage of P vivax malaria
leads to repeated relapses, morbidity, and persistent infection.
It has long been suggested that it may be the total dose of
primaquine that is important in the treatment of the hypnozoite
stage rather than the length of the course (Schmidt 1977). If a higher
dose of primaquine could be administered safely over a shorter
period of time, it may improve adherence rates, thus reducing
relapse rates and morbidity and mortality resulting from P vivax
infection. There are small trials from the 1970s that suggest that
shorter, higher-dose regimens were as eEicacious as the 14-day
courses (Clyde 1977; Saint-Yves 1977). At the time of the previous
Cochrane Review (Galappaththy 2013), there were no recent large
high-quality trials that had investigated the use of the same total
dose as the standard regimen (210 mg), or higher total doses, given
over either shorter or longer periods. We planned to include any
such trials in this Cochrane Review.
Why it is important to do this review
The use of primaquine for radical cure of P vivax malaria continues
to pose a therapeutic dilemma for healthcare providers in areas
without adequate screening for G6PD status. Clinicians must
either choose to give primaquine and risk haemolysis if the
patient is G6PD-deficient, or withhold treatment and accept the
complications of ongoing parasite infection and relapses. This is
why when clinicians choose to treat with primaquine they prefer
a lower dose over a more prolonged period, which then risks
diEiculties with adherence and thus reduced eEectiveness.
We know from the previous Cochrane Review on primaquine with
chloroquine for radical cure that the standard 14-day regimen of
0.25 mg/kg/day (15 mg per day or 210 mg total dose) is better than
shorter regimens of similar daily doses and placebo (Galappaththy
2013). In fact, the regimen of 0.25 mg/kg/day for five days of
primaquine did not reduce recurrences compared to treating with
chloroquine alone.
A major problem with the radical cure of P vivax is diEiculty
with the adherence to the 14-day course of primaquine, which
has led to many countries shortening the regimen. Peru was one
such example, although a study revealed that patients oRen still
discontinued the therapy aRer around three days, when they
started to feel better (Grietens 2010). A study that compared directly
observed therapy (DOT) for 14 days of primaquine versus non-DOT
primaquine found that the P vivax recurrence rate was significantly
lower in the DOT group (Takeuchi 2010). These problems have
led to a more urgent call for shorter treatment regimens. Various
trials are investigating regimens that revise dosing and duration
of treatment in order to improve adherence and reduce the
potential for incomplete treatment and development of resistance.
As mentioned previously, the significance of the total cumulative
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primaquine dose given, rather than the length of the course, is
one avenue of investigation. In areas where G6PD screening is
present, using higher dosing regimens over shorter time periods, if
at least similarly eEicacious, could improve adherence and reduce
morbidity associated with P vivax parasitaemia.
World Health Organization guidelines suggest a higher dosing
regimen of primaquine for the tropical, frequent-relapsing strains
of P vivax in East Asia and Oceania (WHO 2015), although the
previous Cochrane Review, Galappaththy 2013, did not find any
trials assessing this. Investigating the evidence base for this is
therefore important. The 2015 WHO guidelines also suggest an
alternate dosing regimen of weekly primaquine, which may be
safer in patients with G6PD deficiency. As the previous Cochrane
Review included data from only one trial assessing this, it is useful
to investigate whether there is further evidence to substantiate this
guidance.
In this Cochrane Review, we have excluded comparisons between
blood-stage drug (chloroquine/ACT) with and without primaquine,
as the rationale for primaquine use has been suEiciently
demonstrated in a previous Cochrane Review (Galappaththy 2013).
Similarly, we have not included comparisons between diEerent
blood-stage drugs in which the same dose of primaquine was
used; an update to an existing Cochrane Review, Gogtay 2013,
is in progress and will address this. However, we planned to
stratify our results according to partner drug, as there is increasing
evidence that primaquine is metabolized via the cytochrome P450
2D6 (CYP2D6) pathway (Bennett 2013), and eEicacy may thus be
aEected if the blood-stage antimalarial drug is a CYP2D6 inhibitor
(Baird 2018). This review excluded comparisons that do not use
the standard (0.25 mg/kg/day) or high-standard (0.5 mg/kg/day)
regimens of 14 days of primaquine in the control groups. Also, it
did not include comparisons of primaquine regimens of 0.25 mg/
kg/day for less than 14 days, as Galappaththy 2013 has already
assessed these shorter regimens at this dose.
There is currently a lack of consensus among studies as to what
the minimum time frame for follow-up of relapse in P vivax malaria
should be. The WHO guidance on clinical trials in malaria sets out
standard follow-up for blood (or schizontal) stage infection as 28
days aRer treatment commencement, but has no clear definition on
the follow-up period for radical cure in primaquine studies. It states
that "follow up varies from three months to a year in the literature,
and should be adapted to regional parasite characteristics" (WHO
2009). In a recent review, John 2012 described relapse of the
tropical frequently relapsing strain of P vivax as typically three
weeks, but this varies according to blood-stage treatment: "three
weeks following quinine therapy" and "six to eight weeks following
chloroquine" (White 2011). With exposure to primaquine - even if
radical cure is not achieved - relapses may occur at longer intervals
(Sutanto 2013). In the Cochrane Review (Galappaththy 2013), the
follow-up period started 30 days aRer completing primaquine
treatment. Relapse is frequently defined as the presence of P vivax
parasites more than 28 to 30 days aRer the full course of primaquine
in people living in a non-endemic area (Looareesuwan 1997). Due to
the varying lengths of treatment and relapse time in P vivax malaria,
28 days from treatment completion may not allow true assessment
of radical cure. It also makes assessment of the weekly primaquine
regimen diEicult, as the follow-up time should start before the
eight-week treatment course has finished. In this Cochrane Review
we planned to assess parasitaemia at three, six, and 12 months'
follow-up, in keeping with WHO guidance. We intended to describe
the length of follow-up across studies, and then group them into
meaningful lengths of follow-up, depending on the regimen.
Attention is needed to the problems of lack of completion of
long treatment courses and potential insuEicient dosing in some
geographical areas, while maintaining daily doses within a safe
range. We compare the eEicacy and safety of alternative schedules
to those currently recommended, or those with insuEicient
evidence in current recommendations. Specifically, we intended to
answer the following questions by comparing alternative regimens
with total adult dose of over 210 mg to the standard 14-day regimen
of primaquine (0.25 mg/kg/day,15 mg adult daily dose, total dose
210 mg), or the high-standard 14-day regimen (0.5 mg/kg/day,30
mg adult daily dose, total dose 420 mg).
• Is a shorter, higher daily dose regimen with same or higher total
dose, given over seven days, as (or more) eEicacious and safe
as the standard or high standard regimens given over 14 days?
(Comparisons 1 and 4)• Is the high-standard 14-day regimen, with higher daily and total
dose, as (or more) eEicacious and safe as the standard 14-day
course, in all areas and/or where it was formerly recommended
(East Asia and Oceania)? (Comparison 2)• Is a weekly dosing regimen with higher daily dose given one
day a week and with either higher or lower total dose, as (or
more) eEicacious and safe as the standard or high-standard 14-
day regimens? (Comparison 3)
O B J E C T I V E S
To assess the eEicacy and safety of alternative primaquine
regimens with total adult dose >210 mg for radical cure of P vivax
malaria compared to the standard or high-standard 14 days of
primaquine (0.25 mg/kg/day or 0.5 mg/kg/day, total adult dose
210 mg or 420 mg), as well as comparison of these two WHO-
recommended regimens.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs). We excluded quasi-RCTs.
Types of participants
Adults and children with confirmed clinical and parasitological
(light microscopy or PCR, or both) diagnosis of P vivax malaria.
We included trials that excluded people with G6PD deficiency and
trials that included populations that had or had not been screened
for G6PD deficiency. People with mixed malaria infections were
excluded.
Types of interventions
Intervention
Any regimen of either chloroquine or an artemisinin-based
combination therapy (ACT) plus primaquine at total adult dose
>210 mg in any of the following categories.
Daily doses higher than 0.25 mg/kg/day (15 mg daily adult dose,
total dose 210 mg) for 14 days.
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• Shorter regimens with the same or higher total dose than
the regimen they are being compared to i.e. standard or high
standard regimen.• Weekly dosing regimens.
Control
WHO-defined standard regimen of 14 days of primaquine at 0.25
mg/kg/day (15 mg daily adult dose, total dose 210 mg), or high-
standard regimen of 0.5 mg/kg/day for 14 days (30 mg adult daily
dose, total dose 420 mg), plus either chloroquine or an ACT as the
treatment for blood-borne infection. Where possible, we stratified
by the blood schizonticidal agent.
Types of outcome measures
Primary outcomes• P vivax parasitaemia (detected by light microscopy or PCR, or
both) at 3, 6, and 12 months' follow-up. We planned to describe
this as recurrences of P vivax malaria due to the previously
mentioned diEiculties in distinguishing between relapse and re-
infection.
Secondary outcomes• P vivax parasitaemia (detected by light microscopy or PCR, or
both) at one to three months' follow-up.
Adverse events• Serious adverse events (fatal, life-threatening, or requiring
hospitalization).• Adverse events that result in discontinuation of treatment.• Anaemia or change in haemoglobin status.• Other adverse events.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress).
Electronic searches
We searched the following databases using the search terms
and strategy described in Appendix 1: the Cochrane Infectious
Diseases Group Specialized Register (2 September 2019); the
Cochrane Central Register of Controlled Trials (CENTRAL, 2018,
Issue 12, published in the Cochrane Library); MEDLINE (PubMed,
1946 to 2 September 2019); Embase (Ovid, 1947 to 2 September
2019); and LILACS (Bireme, 1982 to 2 September 2019). We
also searched the World Health Organization (WHO) International
Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/),
and ClinicalTrials.gov (clinicaltrials.gov/ct2/home), for trials in
progress, on 2 September 2019, using "primaquine" and "vivax" as
search terms.
Searching other resources
We checked the reference lists of all studies identified by the above
methods for additional potentially relevant studies. We contacted
researchers working in the field and the WHO for unpublished and
ongoing trials. We also searched the reference lists and included
studies of the Cochrane Review Galappaththy 2013.
Data collection and analysis
Selection of studies
Two review authors independently screened the titles and
abstracts of the search results to identify potentially eligible trials,
coding the articles as either 'retrieve' or 'do not retrieve'. We
obtained the full-text reports of potentially eligible trials and
assessed them for inclusion in the review using a predesigned
eligibility form based on the inclusion criteria. Any discrepancies
were resolved through discussion or by consulting a third review
author if necessary. Where necessary, we contacted the trial
authors for clarification of trial methods. We listed the excluded
trials and the reasons for their exclusion in a Characteristics of
excluded studies table. Where there were multiple reports relating
to the same trial, we planned to include all reports and collate data.
We detailed the trial selection process in a PRISMA diagram.
Data extraction and management
Two review authors independently extracted data from the
included trials using a data extraction form designed specifically for
this review, in keeping with Cochrane guidance (Higgins 2011).
For each included trial we extracted a minimum of the following
data where available.
• Study design.• Endemicity/population demographics.• G6PD status of participants (known/unknown).• CYP2D6 status (if available).• Blood-stage antimalarial drug choice.• Dose/duration/timing of treatment arms.• Supervised or non-supervised therapy.• Duration of follow-up.• Adverse events.• Reported outcomes.
Any diEerences in data extraction were resolved through discussion
or by consulting a third review author if necessary. We entered the
extracted data into Review Manager 5 (RevMan 5) (Review Manager
2014). Where necessary, we contacted the authors of primary trials
regarding missing data or methodological details of the trial. We
noted any limitations in the included studies.
We grouped comparisons as illustrated in Table 1.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included trial using the Cochrane 'Risk of bias' assessment tool,
discussing any diEerences of opinion. In the case of missing or
unclear information, we contacted the trial authors for clarification.
We summarized the results in the 'Risk of bias' tables in the
Characteristics of included studies tables (Higgins 2011).
Measures of treatment e@ect
For dichotomous data, we compared interventions using risk
ratios (RRs) to measure treatment eEect. Where trial authors
presented data as odds ratios, we recalculated the eEect. We
defined statistical significance as P < 0.05 and calculated 95%
confidence intervals (CIs) for all results. For comparable trials, we
performed meta-analyses if there were suEicient data.
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We also extracted measures of rate ratio and hazard ratio when
reported by trials, and summarized these in appendices.
Unit of analysis issues
We split trials that included more than two comparison groups and
analysed them as individual pair-wise comparisons. If there was a
shared control group, we split the control group so that participants
were only counted once in the overall meta-analysis.
Dealing with missing data
We analysed missing data using available-case analysis if we judged
the trial to be at low risk of bias for incomplete outcome data.
We attempted to contact trial authors to obtain missing or unclear
data. If the missing data rendered the result uninterpretable,
we excluded the data from meta-analyses and clearly stated the
reason for exclusion. If the missing data meant that results were
interpretable but likely to be at high risk of bias, we planned to use
imputation methods to investigate the impact of the missing data.
We analysed extracted data on an intention-to-treat basis where
there were no missing data.
Assessment of heterogeneity
We inspected forest plots for overlapping CIs. We also applied the
Chi2 test as a statistical test for the presence of heterogeneity,
with a P value of 0.10 used to indicate statistical significance, and
we computed the I2 statistic to quantify the percentage of the
variability in eEect estimates that was due to heterogeneity rather
than sampling error (chance). We investigated possible causes of
heterogeneity by subgroup analysis. If substantive heterogeneity
persisted, defined as an I2 statistic value of greater than 50%, we
used a random-eEects meta-analysis.
Assessment of reporting biases
We planned to examine the likelihood of reporting bias using funnel
plots, however the number of included trials was insuEicient to
permit this.
Data synthesis
We analysed the data using RevMan 5 (Review Manager 2014).
We assessed the certainty of the evidence for each outcome
measure using the GRADE approach, and we constructed 'Summary
of findings' tables using GRADEpro GDT (GRADEpro GDT 2015).
We grouped the analyses by drug regimen and stratified results
according to blood-stage partner drug (if diEerent blood-stage
antimalarials were used). Length of follow-up varied with regimens
and between studies. We conducted an inventory of length of
follow-up against each drug regimen and then grouped P vivax
parasitaemia recurrence by appropriate groupings for length of
follow-up and stratified data accordingly.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analyses according to geographical
region/endemicity and directly observed therapy (DOT) or non-
DOT. We had planned to perform a subgroup analysis according to
CYP2D6 status, however data were insuEicient to permit this.
Sensitivity analysis
We planned to assess the risk of bias of studies that contributed
data to the meta-analyses for the prespecified outcomes with
sensitivity analyses against concealment of allocation.
R E S U L T S
Description of studies
Results of the search
Our database update search, conducted up to 2 September 2019,
identified 44 studies. We excluded 38 articles during abstract
screening, and selected six studies for full-text review. We excluded
four studies with reasons provided, and included one new reference
with outcome data for a previously ongoing study (Taylor 2019
MULTI) ,and one new reference with outcome data for an already
included study that had not provided any data in the previous
version of this review (Chu 2019 THA). Following this update search,
this review now contains 11 included studies, 29 excluded studies
and one ongoing study. The search results and screening process
for this update are presented in a PRISMA diagram in Figure 1.
 
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
14
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Figure 1.   Study flow diagram.
 
Included studies
We included 11 studies (of 11 trials) in our quantitative analysis.
One trial was multinational and conducted in Africa (Ethiopia) and
Asia (Afghanistan, Indonesia, and Vietnam) (Taylor 2019 MULTI).
Four trials were conducted in South America: one in Colombia
(Carmona-Fonseca 2009 COL), one in Brazil (Abdon 2001 BRA), and
two in Peru (Solari-Soto 2002 PER; Durand 2014 PER). Six trials were
conducted in Asia: one in Pakistan (Leslie 2008 PAK), two in Thailand
(Bunnag 1994 THA; Chu 2019 THA), and three in India (Rajgor 2014
IND; Pareek 2015 IND; Saravu 2018 IND).
Eight trials were funded by not for profit organizations, government
agencies, or academia. One trial was funded by the drug
manufacturer (Pareek 2015 IND), and two trials did not report their
source of funding (Bunnag 1994 THA; Abdon 2001 BRA).
All 11 trials included data for adults, and six trials included children
under the age of 10 years (Solari-Soto 2002 PER; Leslie 2008 PAK;
Carmona-Fonseca 2009 COL; Durand 2014 PER; Chu 2019 THA;
Taylor 2019 MULTI). Two trials (Chu 2019 THA; Taylor 2019 MULTI)
included children from the age of six months.
Nine trials excluded pregnant women, and two trials did not specify
whether or not pregnant women were included (Bunnag 1994 THA;
Solari-Soto 2002 PER). Eight trials specified that lactating women
were excluded, while the remaining three trials did not provide
details regarding this (Bunnag 1994 THA; Solari-Soto 2002 PER;
Carmona-Fonseca 2009 COL). Only one trial included people with
G6PD deficiency (Leslie 2008 PAK). Eight trials excluded people
with G6PD deficiency (Bunnag 1994 THA; Carmona-Fonseca 2009
COL; Durand 2014 PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu
2018 IND; Chu 2019 THA; Taylor 2019 MULTI), and two trials did not
specify whether or not people with G6PD deficiency were included
(Abdon 2001 BRA; Solari-Soto 2002 PER).
All of the trials used microscopy for diagnosis of parasitaemia. Four
trials carried out polymerase chain reaction (PCR) genotyping of
vivax parasitaemia as well (Durand 2014 PER; Rajgor 2014 IND;
Pareek 2015 IND; Saravu 2018 IND).
Two trials used diEerent doses or regimens of chloroquine within
trial arms, but as both confirmed that parasitaemia had resolved
following treatment, we still included them in the review (see
Characteristics of included studies) (Bunnag 1994 THA; Abdon 2001
BRA). None of the included trials described the CYP2D6 status of
participants.
Excluded studies
We excluded 29 studies during full-text screening; see details in
Characteristics of excluded studies.
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Risk of bias in included studies
A summary of the 'Risk of bias' assessments is presented in Figure
2. Full details are shown in the Characteristics of included studies
tables.
 
Figure 2.   ‘Risk of bias' summary: review authors' judgements about each ‘Risk of bias' item for each included
study.
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Abdon 2001 BRA ? ? - - + + ?
Bunnag 1994 THA ? ? + ? - ? ?
Carmona-Fonseca 2009 COL ? ? - - + ? +
Chu 2019 THA + ? - - ? + +
Durand 2014 PER + + - - + + +
Leslie 2008 PAK - - - + - + +
Pareek 2015 IND + + + ? + - ?
Rajgor 2014 IND + - - + - ? +
Saravu 2018 IND + ? - - - + +
Solari-Soto 2002 PER ? ? - ? + ? +
Taylor 2019 MULTI + + + + ? + +
 
Allocation
Six trials described adequate methods of treatment randomization
and were judged to be at low risk of selection bias (Durand
2014 PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018 IND;
Chu 2019 THA; Taylor 2019 MULTI). We assessed one trial as
being at high risk of bias as it used two diEerent methods of
randomization depending on location, using house numbers or
sequential patient numbers (Leslie 2008 PAK). Four trials did not
detail the randomization process (Bunnag 1994 THA; Abdon 2001
BRA; Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL).
Two trials used sealed envelopes to conceal allocation (Durand
2014 PER; Pareek 2015 IND) and an independent statistician held
the group assignments in one trial (Taylor 2019 MULTI), so these
three trials were assessed as being at low risk of bias. We assessed
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two trials with no concealment of treatment allocation as at high
risk of bias (Leslie 2008 PAK; Rajgor 2014 IND), while six trials
provided no information on whether or not allocation concealment
was used (Bunnag 1994 THA; Abdon 2001 BRA; Solari-Soto 2002
PER; Carmona-Fonseca 2009 COL; Saravu 2018 IND; Chu 2019 THA).
Blinding
Eight trials were open-label and were assessed as at high risk of
performance bias (Abdon 2001 BRA; Solari-Soto 2002 PER; Leslie
2008 PAK; Carmona-Fonseca 2009 COL; Durand 2014 PER; Rajgor
2014 IND; Saravu 2018 IND; Chu 2019 THA). The remaining three
trials reported blinding of participants and personnel, and were
classified as being at low risk of performance bias (Bunnag 1994
THA; Pareek 2015 IND; Taylor 2019 MULTI). FIve trials were at high
risk of detection bias (Abdon 2001 BRA; Carmona-Fonseca 2009
COL; Durand 2014 PER; Saravu 2018 IND; Chu 2019 THA); they
were all open-label trials that did not report any details of blinding
outcome assessment. Three trials were at unclear risk of detection
bias. They were either double-blind trials that did not report any
details as to whether microscopy was blinded or whether there was
double reading of smears (Bunnag 1994 THA; Pareek 2015 IND), or
an open-label trial that mentioned double-checking of smears but
did not clarify whether outcome assessment was blinded (Solari-
Soto 2002 PER). Three trials were at low risk of detection bias; they
reported blinding of the microscopists who read the slides (Leslie
2008 PAK; Rajgor 2014 IND; Taylor 2019 MULTI).
Incomplete outcome data
Five trials had low rates of attrition with losses accounted for and
so were judged as at low risk of attrition bias (Abdon 2001 BRA;
Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL; Durand 2014
PER; Pareek 2015 IND). We assessed four trials as at high risk of
attrition bias. Bunnag 1994 THA had unexplained, significant loss to
follow-up (more than three-quarters of participants by the end of
the trial), making the results uninterpretable. Leslie 2008 PAK had a
higher loss to follow-up in the intervention group compared to the
control group (6% loss versus 1% loss). Rajgor 2014 IND had a high
percentage of missing results at six months. Saravu 2018 IND had
a high percentage of loss to follow-up in both arms by six months.
Two trials were assessed as at unclear risk of attrition bias (Chu
2019 THA; Taylor 2019 MULTI), both had high rates of dropouts, but
this was aRer one year and rates were balanced between groups
and reasons for dropping out were provided.
Selective reporting
We judged six trials to have adequately reported on either
prespecified or expected outcomes (Abdon 2001 BRA; Leslie 2008
PAK; Durand 2014 PER; Saravu 2018 IND; Chu 2019 THA; Taylor
2019 MULTI). Risk of reporting bias was unclear for four trials as no
protocols were available (Bunnag 1994 THA; Solari-Soto 2002 PER;
Carmona-Fonseca 2009 COL; Rajgor 2014 IND). We assessed Pareek
2015 IND as being at high risk of reporting bias because compliance
was added as an outcome, primaquine levels were not reported as
planned, and PCR results were not well-detailed.
Other potential sources of bias
We assessed eight trials as at low risk of other bias (Solari-Soto 2002
PER; Leslie 2008 PAK; Carmona-Fonseca 2009 COL; Durand 2014
PER; Rajgor 2014 IND; Saravu 2018 IND; Chu 2019 THA; Taylor 2019
MULTI). We assessed Pareek 2015 IND to be at unclear risk of other
bias as it was funded by the drug company that manufactured the
primaquine preparations, and the authors were employees of the
company. Another two trials, for which funding was not detailed,
were also assessed as at unclear risk of other bias (Bunnag 1994
THA; Abdon 2001 BRA).
E@ects of interventions
See: Summary of findings 1 Summary of findings table 1 (main
comparison); Summary of findings 2 Summary of findings table 2;
Summary of findings 3 Summary of findings table 3; Summary of
findings 4 Summary of findings table 4
Comparison 1: 0.5 mg/kg/day for seven days versus standard
0.25 mg/kg/day for 14 days
This comparison aimed to investigate whether a shorter, higher-
dose regimen of primaquine over seven days is as eEicacious as
standard treatment over 14 days to determine whether the total
dose rather than the length of treatment is an important factor
(total dose 210 mg).
Five trials in India and South America compared 0.5 mg/kg/day
of primaquine for seven days versus the standard (0.25 mg/kg/
day) 14-day regimen (same total dose 210 mg) (Abdon 2001 BRA;
Solari-Soto 2002 PER; Durand 2014 PER; Rajgor 2014 IND; Pareek
2015 IND). Pareek 2015 IND used a sustained-release preparation
of primaquine in two of the study arms (0.5 mg/kg/day sustained
release and 0.25 mg/kg/day sustained release) and standard
primaquine at 0.25 mg/kg/day in a third arm. We included the
0.5 mg/kg/day sustained release in the analysis and combined the
results with the standard preparation at the same dose used for the
other trials, but used only the standard-preparation group of 0.25
mg/kg/day in the study as the control group and did not include the
arm of 0.25 mg/kg/day sustained release preparation.
Three trials excluded people with G6PD deficiency, while two
trials did not provide this information (Bunnag 1994 THA; Solari-
Soto 2002 PER). All but one trial excluded women who were
pregnant or lactating (Solari-Soto 2002 PER did not provide details).
Participants were a mixture of adults and children over one-year
old. All trials used microscopy for diagnosis, and only Pareek 2015
IND did not use supervised treatment. Two trials gave chloroquine
and primaquine courses simultaneously (Abdon 2001 BRA; Durand
2014 PER), while the other three trials administered primaquine
following the chloroquine course. No trials stratified by age, so
results were combined.
Eicacy
There was minimal diEerence in the number of malaria recurrences
between groups at six to seven months' follow-up (risk ratio
(RR) 0.96, 95% confidence interval (CI) 0.66 to 1.39; 4 trials, 1211
participants; low-certainty evidence; Analysis 1.1). One trial only
followed participants for two months (Solari-Soto 2002 PER), and
so was not part of the main analysis.
We had planned to perform a sensitivity analysis based on risk
of bias for allocation concealment (which would have involved
removing Rajgor 2014 IND from the meta-analysis), but we decided
that as the remaining trials were all at high risk of bias for
blinding and thus quality was generally low, we would not conduct
a sensitivity analysis but address these issues in our GRADE
assessment.
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Two trials PCR-adjusted their results to diEerentiate between
relapses and new infections at six to seven months' follow-up. In
Durand 2014 PER, PCR-adjusted results showed a 31% reduction in
recurrence (24% reduction with light microscopy) with the regimen
of 0.5 mg/kg/day for seven days compared with the standard 14-
day course, while in Rajgor 2014 IND, PCR-adjusted results showed
a 159% increase in recurrence (25% increase in recurrence with
light microscopy) with the regimen of 0.5 mg/kg/day for seven
days compared to the standard 14-day regimen (Analysis 1.2).
We decided that these results could not be combined in a meta-
analysis, as PCR techniques can diEer, and there were high levels of
heterogeneity.
We performed a subgroup analysis according to geographic region
(Analysis 1.3). For trials in South America, the regimen of 0.5
mg/kg/day for seven days led to a 30% reduction in P vivax
recurrences compared to a 19% increase in recurrences for trials
in Asia, although CIs were wide and included no eEect for both
subgroups (South America: RR 0.70, 95% CI 0.39 to 1.26; 2 trials,
397 participants; Asia: RR 1.19, 95% CI 0.73 to 1.94; 2 trials, 814
participants). Only one trial did not use directly observed therapy
(DOT) (Pareek 2015 IND). Subgroup analysis (Analysis 1.4) showed
that with DOT there was minimal diEerence in recurrences at six to
seven months between treatment regimens (RR 0.98, 95% CI 0.67
to 1.43; 1017 participants) compared to a reduction of about half
of recurrences with the regimen of 0.5 mg/kg/day for seven days
when treatment was not supervised (RR 0.48, 95% CI 0.04 to 5.20;
194 participants).
Adverse events
No serious adverse events were reported in either group (5
trials, 1427 participants, Analysis 1.5). The number of participants
experiencing adverse events leading to discontinuation of
treatment was similar in both groups (very low-certainty evidence,
RR 1.04, 95% CI 0.15 to 7.38; 5 trials, 1427 participants; Analysis
1.6). Only one study reported on adverse events during chloroquine
administration (Rajgor 2014 IND), with more occurring in the group
receiving 0.5 mg/kg/day for seven days than the standard 14-day
group (RR 9.40, 95% CI 0.51 to 174.01; one trial, 779 participants;
Analysis 1.7). There was no diEerence in adverse events occurring
during primaquine administration (RR 1.64, CI 0.75 to 3.57; 2
trials,1019 participants; Analysis 1.8). There was no diEerence
between arms in other adverse events (RR 0.56, 95% CI 0.23 to 1.36;
2 trials,135 participants; Analysis 1.9).
One trial reported on change in haemoglobin status (Pareek 2015
IND), with one participant out of 120 in the group receiving 0.5 mg/
kg/day for seven days becoming anaemic, versus no participants
out of 120 in the standard 14-day regimen group (very low-certainty
evidence, RR 3.00, 95% CI 0.12 to 72.91; 240 participants; Analysis
1.10).
Durand 2014 PER noted that the arms with higher daily primaquine
dose did not present significantly higher frequency of the five
symptoms (fever, chills, headache, muscular pain, and dark urine)
monitored during treatment.
Details on the nature of the adverse events are reported in Appendix
2.
Comparison 2: high-standard 0.5 mg/kg/day for 14 days versus
standard 0.25 mg/kg/day for 14 days
The World Health Organization (WHO) recommends higher doses of
primaquine (0.5 mg/kg/day) for 14 days in East Asia and Oceania.
We intended to examine whether this high-standard regimen was
more eEicacious in areas where it is currently recommended (East
Asia and Oceania), as well as in all other areas where it has been
used due to perceived resistance or strain diEerences.
Two trials compared the high-standard 14-day course with the
standard (0.25 mg/kg/day) 14-day course, both carried out in
adults in India (Rajgor 2014 IND; Saravu 2018 IND). Both trials
excluded pregnant/lactating women and G6PD-deficient patients.
In Rajgor 2014 IND, participants were treated with chloroquine,
with the primaquine regimen (which was supervised) given aRer
completion of the chloroquine course. In Saravu 2018 IND,
participants were treated with either chloroquine or an artemisinin-
based combination therapy (ACT) (artesunate with doxycycline
or artemether-lumefantrine), and (unsupervised) primaquine was
given aRer completion of the blood-stage treatment. We planned
to stratify results according to blood-stage treatment; however,
Saravu 2018 IND combined the results for both blood-stage
treatments, so we were unable to separate results according to
partner drug. Only the blood-stage drugs given to participants who
had recurrences were described. Results from the two studies are
presented separately in subgroups, but are also combined.
Eicacy
The combined estimate for both trials suggests little or no
diEerence between the arms: (RR 0.84, 95% CI 0.49 to 1.43; 2
trials, 677 participants, low-certainty evidence, test for subgroup
diEerences, I2 = 0%).
In Rajgor 2014 IND, 21 participants out of 317 in the high-standard
14-day group had a recurrence of vivax malaria compared with
26 out of 322 in the standard 14-day group at six-month follow-
up, giving an 18% reduction in recurrence of parasitaemia in the
high-standard group (RR 0.82, 95% CI 0.47 to 1.43; 639 participants;
Analysis 2.1). P vivax malaria recurrences were also investigated
by PCR to determine whether they were true relapses or new
infections. ARer this adjustment, results showed an 83% increase in
P vivax malaria cases in the high-standard group (RR 1.83, 95% CI
0.62 to 5.40; Analysis 2.2). Rajgor 2014 IND was at high risk of bias
for allocation concealment.
Saravu 2018 IND was a small open-label pilot trial in which
participants were given either chloroquine or ACT depending on
clinician's judgement of severity. 78% of participants were given
chloroquine (76% in the standard arm and 80% in the high-
standard arm). In Saravu 2018 IND, two out of 18 participants in
the high-standard 14-day group had a recurrence of P vivax malaria
compared to two out of 20 in the standard 14-day group at six
months' follow-up (RR 1.11, 95% CI 0.17 to 7.09; Analysis 2.1).
Polymerase chain reaction (PCR) genotyping suggested that all four
participants had true relapses of infection.
Adverse events
In Rajgor 2014 IND there were no serious adverse events reported
in either study arm (778 participants). In the high-standard 14-
day group, eight out of 380 participants discontinued treatment
due to adverse events (one participant discontinued chloroquine
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and seven participants discontinued primaquine), compared to
two out of 398 in the standard 14-day group (both participants
discontinued primaquine) (RR 4.19, 95% CI 0.90 to 19.60; 778
participants; Analysis 2.4). In the high-standard arm during
chloroquine treatment, four out of 380 participants experienced
adverse events compared to zero out of 398 in the standard group
(RR 9.43, 95% CI 0.51 to 174.47; 778 participants; Analysis 2.5).
In the high-standard arm during primaquine treatment, 13 out of
380 participants experienced adverse events known to occur with
primaquine, compared to five out of 398 in the standard arm (RR
2.72, 95% CI 0.98 to 7.57; 778 participants; Analysis 2.5). These
results could suggest a trend towards higher occurrence of adverse
events in the high-standard 14-day regimen. Details on the nature
of the adverse events are reported in Appendix 2.
No significant adverse events were noted in either group in Saravu
2018 IND.
Comparison 3: 0.75 mg/kg/week for eight weeks versus high-
standard 0.5 mg/kg/day for 14 days
This comparison aimed to investigate whether a higher once-
weekly dosing regimen, which may be more beneficial for people
with G6PD deficiency, was as eEicacious as the high-standard 14-
day regimen.
One trial compared weekly 0.75 mg/kg primaquine (45 mg adult
dose) for eight weeks with the high-standard 14-day regimen (0.5
mg/kg/day) (Leslie 2008 PAK). G6PD-deficient participants were
not randomized but were included in the weekly group, although
there only was one G6PD-deficient person included. Pregnant and
lactating women were excluded. Treatment was supervised. It was
not specified whether chloroquine and primaquine were given
concurrently.
Eicacy
Recurrences were more common in the weekly group at eight
months' follow-up (RR 7.00, 95% CI 0.38 to 127.32; 126 participants;
Analysis 3.1). Recurrences remained more common in the weekly
group at 11 months' follow-up (RR 3.18, 95% CI 0.37 to 27.60; 122
participants; very low-certainty evidence; Analysis 3.1). Leslie 2008
PAK was at high risk of bias for allocation concealment, but a
sensitivity analysis could not be done as it was the only trial found
for this comparison.
Adverse events
No serious adverse events (Analysis 3.2) or notable non-serious
adverse events (Analysis 3.4) were reported in either study arm. No
participants had anaemia defined as haemoglobin less than 7 g/dL
(Analysis 3.3).
Comparison 4: 1 mg/kg/day for seven days versus high-
standard 0.5 mg/kg/day for 14 days
This comparison aimed to investigate whether shorter, higher
doses of primaquine over seven days are as eEective as the
high-standard 14-day regimen; i.e. to determine whether the total
dose rather than the length of treatment is the important factor
(total dose 420 mg primaquine). Two trials conducted in Ethiopia,
Afghanistan, Indonesia, Thailand, and Vietnam compared 1 mg/
kg/day (adult dose 60 mg) of primaquine for seven days with
the high-standard 14-day course (0.5 mg/kg/day, adult dose 30
mg/day) (Chu 2019 THA; Taylor 2019 MULTI), administering the
regimen with either chloroquine or an ACT (dihydroartemisinin-
piperaquine (DHA-PPQ). We stratified the results accordingly. Both
trials excluded people with G6PD deficiency, however, both trials
included those with G6PD deficiency in parallel observational
cohorts. Women who were pregnant or lactating were excluded.
Participants were a mixture of adults and children over six months
old. Both trials used microscopy for diagnosis, and both trials used
supervised treatment. Taylor 2019 MULTI gave chloroquine or DHA-
PPQ and primaquine courses simultaneously, while Chu 2019 THA
did not specify whether primaquine was given concurrently, before,
or aRer blood-stage drug. No trials stratified by age, so results were
combined.
Eicacy
Primary outcome
Little or no diEerence was detected in recurrence of P vivax
malaria aRer 12 months between 1 mg/kg/day for seven days
compared with the high-standard 14-day regimen in two trials (RR
1.03, 95% CI 0.82 to 1.30; 2526 participants, moderate-certainty
evidence, Analysis 4.1). Rate ratios and hazard ratios support the RR
estimate and are reported in Appendix 3 The results were similar
for the chloroquine subgroup (RR 0.91, 95% CI 0.67 to 1.22; 1404
participants) and for the DHA-PPQ subgroup (RR 1.24, 95% CI 0.87
to 1.77; 1122 participants). Results were also similar for subgroups
by geographical region (Analysis 4.2).
Only one trial (Chu 2019 THA) reported risk ratios at six and three
months. There was little or no diEerence detected in recurrence
of P vivax malaria aRer six months (RR 1.10, 95% CI 0.61 to 1.97;
1 RCT, 474 participants; Analysis 4.3) and aRer three months (RR
0.94, 95% CI 0.41 to 2.14; 1 RCT, 522 participants; Analysis 4.4).
Results subgrouped by blood-stage drug were similar, but results
were imprecise due to wide 95% CIs.
Taylor 2019 MULTI did not report risk ratios at six and three months
that could be pooled with the main results. Rate ratios from this
study are presented in Appendix 3, and they also show little or no
diEerence in recurrences between the two arms.
Secondary outcome
Taylor 2019 MULTI reported on short-term follow-up of P vivax
parasitaemia. Little or no diEerence was detected for P vivax
parasitaemia aRer 28 days (RR 0.67, 95% CI 0.11 to 3.99; 1872
participants; Analysis 4.5), and aRer 42 days (RR 1.00, 95% CI 0.35 to
2.85; 1872 participants; Analysis 4.5). The estimates are uncertain
due to very wide 95% CIs.
Adverse events
There may be moderate to large increase in serious adverse events
in the 1.0 mg/kg/day primaquine for seven days group compared
with the high-standard 0.5 mg/kg/day at 42 days (RR 12.03, 95%
CI 1.57 to 92.30; 1872 participants; low-certainty evidence; Analysis
4.6), and at one year follow-up (RR 3.61, 95% CI 1.35 to 9.68;
1872 participants; Analysis 4.6). The absolute numbers reported
by Taylor 2019 MULTI at 42 days and one year were 12 and 18
serious adverse events in the primaquine 1 mg/kg/day for seven
days group among 935 participants compared to one and five
in the control arm among 937 participants, respectively. Of the
12 serious adverse events reported at 42 days in the 1 mg/kg/
day group, nine were regarded as being possibly, probably, or
definitely related to primaquine (details of each event from Taylor
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2019 MULTI supplementary files are given in Appendix 2). At one
year, an additional six serious adverse events deemed unrelated to
primaquine were reported in the 1 mg/kg/day group. Only one of
the five serious adverse events in the high-standard 14 day regimen
(observed by 42 days) was deemed probably related to primaquine
(Appendix 2).
Chu 2019 THA only provides a narrative summary and does not
report serious adverse events per group. The authors noted that
there were 30 serious adverse events reported; most common
were methaemoglobinaemia (n = 10), haemolysis (n = 3), and
presumed bacterial infection (n = 10). Four deaths occurred. None
was considered related to the study drugs (follow-up, up to 42
days).
There is probably no diEerence in adverse events leading to
discontinuation of treatment between both groups (RR 2.50, 95%
CI 0.49 to 12.87; 2 trials, 2526 participants; very low-certainty
evidence; Analysis 4.7). However, the evidence is very uncertain due
to risk of bias and wide 95% CIs.
Taylor 2019 MULTI reported 1819 adverse events among the 935
participants in the seven-day primaquine group and 1732 events
among the 937 participants in the 14-day primaquine group; Chu
2019 THA reported 169 events among the 327 participants in
the seven-day primaquine group and 173 events among the 327
participants in the 14-day primaquine group (Analysis 4.8).
Full details on the nature of adverse events are reported in
Appendix 2.
There is probably no diEerence in haemoglobin status between
both groups (RR 0.93, CI 95% 0.62 to 1.41; 2 trials, 2440 participants;
very low-certainty evidence; Analysis 4.9). However, the evidence is
very uncertain due to risk of bias and wide 95% CIs.
Comparisons 5 and 6: other regimens
0.375 mg/kg/day for 14 days versus standard 14-day regimen
Bunnag 1994 THA compared 0.375 mg/kg/day (adult dose 22.5 mg)
primaquine daily for 14 days with the standard regimen of 0.25 mg/
kg/day for 14 days. There was a high loss to follow-up, with 167
participants enrolled and only 38 completing 18 months' follow-up,
although the loss was equal in both groups at the end of follow-
up. At six months' follow-up there were no episodes of P vivax in
the experimental group (0/40) and two recurrences in the standard-
regimen group (2/33) (RR 0.17, 95% CI 0.01 to 3.34; 73 participants;
Analysis 5.1), although only about half of enrolled participants
were followed up at this time point. No further recurrences were
described in either group up to the end of follow-up at 18 months,
but as described, the high level of unexplained dropout makes
interpretation diEicult.
No formal assessment of adverse events was reported, but it
is mentioned in the study narrative that patients tolerated the
medication well and no serious adverse eEect was seen in either
group.There was no drop in haematocrit, or haemoglobinuria in
either group.
1.17 mg/kg/day for three days versus standard 14-day regimen
One trial delivered the total dose of primaquine (1.17 mg/kg/day
or 70 mg adult dose, total dose 210 mg) over three days versus
the standard (0.25 mg/kg/day) 14-day regimen (Carmona-Fonseca
2009 COL). Recurrences of P vivax malaria were more common
in the group receiving 1.17 mg/kg/day for three days than in the
standard 14-day group at 4 months' follow-up (RR 3.88, 95% CI 2.11
to 7.11; 129 participants; Analysis 6.1).
Adverse events were not reported, although it was noted that there
were no serious adverse events from co-administering primaquine
and chloroquine.
D I S C U S S I O N
Summary of main results
Comparison 1 (main comparison): 0.5 mg/kg/day for seven
days versus standard 0.25 mg/kg/day for 14 days
See Summary of findings 1
We included five randomised controlled trials (RCTs) that compared
0.5 mg/kg/day (adult dose 30 mg) primaquine for seven days with
the standard 14-day regimen (0.25 mg/kg/day). There may be little
or no diEerence in P vivax recurrences at six to seven months when
using the same total dose (210 mg) over seven days as compared
to 14 days (low-certainty evidence). No serious adverse events
were reported. There may be little or no diEerence in the number
of adverse events during primaquine treatment when using the
shorter regimen as compared to the longer regimen.
We do not know whether there is any diEerence in the frequency
of anaemia or discontinuation of treatment between groups (very
low-certainty evidence). Three trials excluded people with G6PD
deficiency, and two did not provide this information, so we do
not know the eEect of the higher daily-dose regimen in this
group. Pregnant and lactating women were either excluded or this
information was not provided.
Comparison 2: high-standard 0.5 mg/kg for 14 days versus
standard 0.25 mg/kg/day for 14 days
See Summary of findings 2
We included two RCTs that compared 0.5 mg/kg/day primaquine
(daily adult dose 30 mg) for 14 days with 0.25 mg/kg/day (daily
adult dose 15 mg) for 14 days, both conducted in India. The total
dose diEered between arms, being 420 mg in the high standard
arm and 210 mg in the standard arm. People with G6PD deficiency
and pregnant or lactating women were excluded. One trial did
not account for whether participants were given chloroquine or
an artemisinin-based combination therapy (ACT) for blood-stage
treatment.
There may be little or no diEerence in P vivax recurrences at six
months with the high-standard 14-day course compared to the
standard 14-day course when given with chloroquine or an ACT. No
diEerences were observed when primaquine was given either with
chloroquine, or with chloroquine or ACT.
No serious events were reported in either trial. We do not
know whether there is a diEerence in adverse events leading to
discontinuation between the high-standard 14-day course and the
standard 14-day course (very low-certainty evidence).
Comparison 3: 0.75 mg/kg/week for eight weeks versus high-
standard 0.5 mg/kg/day for 14 days
See Summary of findings 3
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We included one RCT that compared 0.75 mg/kg (daily adult dose
45 mg) weekly primaquine for eight weeks with the high-standard
14-day regimen (0.5 mg/kg/day, daily adult dose 30 mg). The total
dose was 360 mg in the weekly arm versus 420 mg in the high-
standard arm. G6PD-deficient participants were not randomized
but were included in the weekly primaquine group. Only one G6PD-
deficient participant was detected during the trial and was included
in the weekly group.
We do not know whether weekly primaquine reduces recurrence of
P vivax compared to the high-standard 14-day regimen at eight to
11 months' follow-up (very low-certainty evidence).
No serious adverse events and no episodes of anaemia were
reported.
Comparison 4: 1.0 mg/kg/day for seven days versus high-
standard 0.5 mg/kg/day for 14 days
See Summary of findings 4
We included two RCTS (one a large multicentre trial) that compared
a new high dose of 1 mg/kg/day for seven days with the high-
standard course. The total dose of 420 mg was the same for both
arms. G6PD-deficient participants were excluded from one trial; in
the other trial, patients with G6PD deficiency were excluded from
the randomised trial, but were enrolled into a parallel observational
group receiving weekly primaquine.
There is probably little or no diEerence in recurrences between
1.0 mg/kg/day primaquine for seven days and the high-standard
0.5 mg/kg/day for 14 days course at 12 months follow-up
(moderate-certainty evidence). No diEerences were observed when
primaquine was given with chloroquine or dihydroartemisinin-
piperaquine (DHA-PPQ).
There may be moderate to large increase in serious adverse events
with 1.0 mg/kg/day primaquine for seven days compared with the
high-standard 0.5 mg/kg/day, as reported by one trial (Taylor 2019
MULTI) at 42 days and one-year follow-up (low-certainty evidence);
the other trial reported narrative summary only (Chu 2019 THA). We
do not know if there is diEerence in anaemia at 42 days follow-up
or in adverse events leading to discontinuation (very low-certainty
evidence).
Comparisons 5 and 6: other regimens
Some other included trials evaluated alternative regimens and
doses of primaquine, but these regimens have not been widely
used, and the evidence available from stand-alone trials was
limited.
Overall completeness and applicability of evidence
Although the evidence is currently of low certainty, it appears from
Comparison 1 that using 0.5 mg/kg/day with the same total dose
(210 mg) over seven days may be non-inferior to the regimen of
0.25 mg/kg/day for 14 days. It is likely that this shorter regimen
would promote course completion. No serious adverse events were
reported in the five trials in this comparison. However, this seven-
day regimen was not tested in G6PD-deficient patients in any of
the RCTs meeting our inclusion criteria. This remains a concern in
settings where testing is not available.
We initially planned to evaluate whether the high-standard 14-
day regimen (0.5 mg/kg/day) was more eEective in areas where
recommended by the World Health Organization (WHO) due to
reported resistance or strain diEerences (East Asia and Oceania), as
well as in other areas (WHO 2015). However, the two randomized
clinical trials that compared the eEicacy of high-standard to
the standard regimen were both conducted in India (Rajgor
2014 IND; Saravu 2018 IND), where the high-standard regimen is
not recommended. A recent retrospective case review in French
Guiana (also an area where the high-standard regimen is not
currently recommended) found that recurrences were similar in
both standard and high-standard 14-day regimens (Valdes 2018).
We did not find any RCTs that evaluated whether the high-standard
14-day regimen was more eEective compared to the standard 14-
day regimen for the tropical, frequently relapsing strain of P vivax in
East Asia and Oceania, so we are unable to comment on its eEicacy.
Only one included RCT investigated the weekly primaquine
regimen that is currently recommended by WHO for G6PD-deficient
individuals, and only one G6PD-deficient participant was actually
included in the trial.
We found two trials of a new high dose 1.0 mg/kg/day for
seven days compared to the high standard 0.5 mg/kg/day for 14
days. There is probably no diEerence in frequency of recurrences
between these two regimens. However one of these trials reported
increased serious adverse events in the seven-day arm.
A diEiculty encountered in including and comparing studies was the
variation in dosing and length of follow-up in studies. In general,
there were few well-conducted RCTs that used an evidence-based
standard primaquine regimen (0.25 mg/kg/day for 14 days) as a
comparator. Some trials used the high-standard 0.5 mg/kg/day for
14 days regimen, which is recommended by the WHO in East Asia
and Oceania, as a comparator. However, as noted above, there is
limited clear evidence in this review that the high-standard 0.5 mg/
kg/day 14-day regimen is better than the standard 0.25 mg/kg/day
for 14 days.
We found that trials continue to be conducted where placebo
is used instead of an alternative primaquine regimen, which is
contrary to the evidence available demonstrating its superiority for
reducing recurrences (Galappaththy 2013). This may be because
there is continued reluctance to use primaquine in some national
programmes.
We excluded studies where individuals had mixed malaria
infections so as to assess the eEicacy of treatment on P vivax
malaria alone. Areas endemic for P vivax malaria may also be co-
endemic for Plasmodium falciparum or Plasmodium ovale infection,
or both. However, it should be noted that as part of our screening
process we did not identify any studies where participants with
mixed malaria were included, so we do not think that narrowing our
search criteria impacted the directness of our results.
There was a lack of detailed safety data for some trials, despite
the fact that safety is a particular concern with primaquine use.
Although more recent trials have paid more attention to this issue,
they do not all report the adverse events by arm.
Certainty of the evidence
The overall certainty of evidence for most of the outcomes
was either low or very low. Most results were downgraded for
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imprecision due to wide confidence intervals (CIs) in the meta-
analyses performed. The exception is the recent Comparison 4
using high dose 1 mg/kg/day versus high-standard course for
the eEicacy outcomes, where evidence for non-inferiority was
moderate certainty.
The eEicacy comparison for Comparison 2 (high-standard 14-day
regimen versus the standard 14-day regimen) was also downgraded
for indirectness. Results were based on two trials in adults in India
(Rajgor 2014 IND; Saravu 2018 IND). Rajgor 2014 IND was at risk
of bias as there was no allocation concealment and unexplained
loss to follow-up; this study also contributed most to the meta-
analysis for the comparison of 0.5 mg/kg/day for 7 days versus
standard 14-day regimen, so this study was also downgraded.
Saravu 2018 IND was a small pilot study where participants were
given either chloroquine or an ACT for the blood stage, and which
blood-stage treatment they were given was not stated by outcome
(although appeared balanced between arms). Saravu 2018 IND was
downgraded for imprecision, indirectness, and risk of bias (not
blinded and high rate of loss to follow-up).
We downgraded the Comparison 3 of 0.75 mg/kg weekly
primaquine versus high-standard 14-day regimen for indirectness
as it was based on just one study conducted in Pakistan (Leslie 2008
PAK), with only one G6PD-deficient patient participating. Leslie
2008 PAK was at risk of bias due to the randomization process
used, lack of allocation concealment, and incomplete outcome
data. We downgraded eEicacy outcomes for this comparison for
serious imprecision due to few events and very wide CIs.
Comparison 4 of high-dose 1 mg/kg for seven days versus high-
standard 14-day regimen was downgraded because one of the two
trials was open-label (Chu 2019 THA).
Potential biases in the review process
The strictness of our inclusion criteria to not include trials where
the total dose was less than the total dose of the standard regimen,
and the necessity of having the comparison arm be one of the
WHO-recommended regimens, may have meant that some relevant
comparisons were excluded.
We changed the protocol to include the high-standard 14-day
regimen that WHO recommends in East Asia and Oceania as a
control regimen, as we realized that some trials had used this as
the comparator, and we felt that these comparisons were useful.
However, this may have introduced bias, as the evidence base for
RCTs (including our results) showing the relative eEicacy of this
regimen is limited.
The diEiculty in determining between relapse and re-infection with
P vivax remains a recognized challenge for assessing the eEicacy of
drugs for radical cure.
Agreements and disagreements with other studies or
reviews
Three previous meta-analyses (John 2012; Carmona-Fonseca 2015;
Zuluaga-Idarraga 2015) of this topic have been published. John
2012 did not explicitly compare short and long schedules, and none
of the reviews included the recent high-dose 1 mg/kg/day seven-
day course trials which are evaluated here.
Our findings that 210 mg over seven days may be as eEicacious
as the standard course of 210 mg over 14 days (Comparison 1) are
consistent with findings of other systematic reviews that examined
both randomized and non-randomized studies (Carmona-Fonseca
2015; Zuluaga-Idarraga 2015). The other reviews also confirm
the lack of comparative evidence for the high-standard versus
standard regimens (Comparison 2), whether in the recommended
geographical area or not. However we included additional recent
RCTs using the standard and high-standard schedules that were not
included in Carmona-Fonseca 2015 or Zuluaga-Idarraga 2015. Only
Carmona-Fonseca 2015 included weekly schedules, and like us
identified only a single study (with one G6PD deficient participant)
evaluating 0.75 mg/kg/day once a week for eight weeks compared
to high-standard 14-day regimen (Comparison 3). Comparison 4
includes trials that are not in the other reviews.
Other reviews also commented on the diEiculty of comparing
results due to the varying treatment regimens and length of follow-
up used in clinical trials.
The systematic review and individual patient data analysis of
Commons 2019 showed that the adverse haematological eEects of
primaquine (when given with chloroquine) may be outweighed by
the eEect of preventing anaemia due to malaria relapses by day
42. We have not been able to investigate such a trade-oE using the
studies in this review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Trials available to date do not detect a diEerence in eEicacy
between the regimen of 0.5 mg/kg/day for seven days and
the standard (0.25 mg/kg/day) 14-day regimen in G6PD-normal
patients. Thus, clinicians wanting to prescribe a shorter regimen
to improve treatment completion with the same as standard
overall dose could use this regimen, and no serious adverse events
were reported in G6PD-normal patients taking 0.5 mg/kg/day of
primaquine for seven days. Clinicians considering the regimen of
1 mg/kg/day for seven days should take into account the elevated
numbers of severe adverse events observed.
Implications for research
Further high-quality randomized controlled trials will help improve
the certainty in diEerent settings. Particularly useful would be
studies of the 0.5 mg/kg/day seven-day and high-standard 14-day
regimens in East Asia and Oceania (where the high standard course
is current recommended), and studies testing modified or weekly
regimens in G6PD-deficient patients.
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Participants 120 participants enrolled.
Inclusion criteria
• Confirmed parasitological diagnosis for P vivax malaria.• Age older than 12 years.• Staying in Belém (study area) until the end of the follow-up period (180 days).
Exclusion criteria
• Pregnant and nursing mothers were excluded.• Patients who used antimalarials at least 2 weeks prior to the start of current treatment.• Carriers of mixed malaria.
Diagnosis: microscopy.
G6PD status not stated.
No details CYP2D6 status.
Interventions • Chloroquine 10 mg/kg single dose + primaquine 0.5 mg/kg/day for 7 days.• Chloroquine 150 mg (25 mg/kg total dose) over 3 days, 10 mg/kg day 1, 7.5 mg/kg days 2 and 3 +
primaquine 15 mg/day 14 days.
(Additional arm chloroquine 10 mg/kg + primaquine 0.5 mg/kg for 5 days not included as total dose
(150 mg) less than standard treatment (210 mg))
Although different doses of chloroquine in the 2 arms, all participants had negative parasitaemia with-
in 72 hours.
Primaquine and chloroquine given concurrently.
Supervised treatment.
Outcomes • Relapse• Safety
Follow-up 180 days
Notes Location: Belém, state of Pará, Brazil
Setting: not stated
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details supplied on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details supplied on allocation.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Abdon 2001 BRA  (Continued)
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Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk One loss to follow-up as moved out of area.
Selective reporting (re-
porting bias)
Low risk Unable to find protocol but relapse and standard errors (SEs) reported as
would be expected.
Other bias Unclear risk Funding not stated.
Abdon 2001 BRA  (Continued)
 
 
Study characteristics
Methods RCT
Dates not provided
Participants 167 participants enrolled.
Inclusion criteria
• 15 to 60 years.
Exclusion criteria
• History of previous treatment.• G6PD deficiency.• Mixed infections.
Diagnosis: microscopy.
No details on pregnant/breastfeeding women.
No details CYP2D6 status.
Interventions • Chloroquine + 22.5 mg/day primaquine for 14 days.• Chloroquine + 15 mg/day primaquine for 14 days.
Open randomization to chloroquine treatment – either 300 mg or 450 mg on day 1 of admission. Re-al-
located after recovery of acute symptoms (double-blind RCT). Chloroquine course completed and para-
sitological clearance confirmed prior to randomization to primaquine group (exact time between treat-
ment courses not specified).
Supervised treatment in hospital.
Outcomes • Relapse• Safety
Follow-up 6 months
Notes Location: Thailand
Setting: not stated
Bunnag 1994 THA 
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Funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk 1st step chloroquine is open randomization, then PQ stage randomized. No de-
tails on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Low risk Reported as double-blind.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Reported as double-blind but there were no details as to whether microscopy
was blinded or whether there was double reading of smears.
Incomplete outcome data
(attrition bias)
All outcomes
High risk Unexplained high loss to follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol.
Other bias Unclear risk Funding not disclosed.
Bunnag 1994 THA  (Continued)
 
 
Study characteristics
Methods RCT
September 2003 to September 2006
Participants 133 patients enrolled across 2 arms (total 188 counting arms not included in review)
Inclusion criteria
• Age > 2 years.• P vivax parasitaemia of > 1000 asexual forms/L.• Willingness to participate.• A normal quantitative G6PD screening test was required for those administered > 0.25 mg/kg/day pri-
maquine base, and only individuals with normal G6PD levels were included in the study.
Exclusion criteria
• Pregnant women.• Those with associated acute infectious diseases.• A history of antimalarials intake during the previous 2 weeks.• Presence of diarrhoea or vomiting (> 5 episodes in 24 hours).• Symptoms or signs of severe malaria (according to WHO 2006).• Hypersensitivity to antimalarials or severe undernutrition.
Carmona-Fonseca 2009 COL 
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• Exclusion from the study also followed intake of any antimalarial different from those provided by the
researchers.• Failure to attend follow-up appointments.• Treatment failure during the primary episode (first 28 days of follow-up).• Consent withdrawal.
Diagnosis: microscopy.
No details CYP2D6 status or breastfeeding mothers.
Interventions • Chloroquine (10 mg/kg day 1, 7.5 mg/kg days 2 and 3) + primaquine 1.17 mg/kg/day for 3 days (total
210 mg).• Chloroquine (10 mg/kg day 1, 7.5 mg/kg days 2 and 3) + primaquine 0.25 mg/kg/day for 14 days.
(Additional arms: 0.83 mg/kg day for 3 days (total dose 149.4 mg) and 0.58 mg/kg day for 3 days (total
dose 104.4 mg) not included as total dose less than standard treatment)
Primaquine given simultaneously with chloroquine.
Supervised treatment.
Outcomes • Recurrence of P vivax malaria (parasitaemia after day 28)
Follow-up 120 days
Notes Location: Colombia
Setting: patients that attended the local health clinics in Turbo and El Bagre
Funding: Colciencias (government agency), Dirección Seccional de Salud de Antioquia (DSSA), Universi-
dad de Antioquia
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Details of randomization not given.
Allocation concealment
(selection bias)
Unclear risk No details supplied.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Not blinded.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Not blinded and no mention on blinding in blood smear assessment.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk 2 lost per group, no explanations given, but less than 5% of total across
groups.
Selective reporting (re-
porting bias)
Unclear risk Protocol not found. No safety data were provided (which might have been ex-
pected to have been provided).
Other bias Low risk Government and academic funding.
Carmona-Fonseca 2009 COL  (Continued)
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Study characteristics
Methods RCT
February 2012 to July 2015
Participants 680 participants enrolled.
Inclusion criteria
• ≥6 months• ≥7 kg• uncomplicated P vivax monoinfection
Exclusion criteria
• G6PD deficient by the fluorescent spot test• Pregnant or breastfeeding an infant ≤ 6 months• Hematocrit ≤25%• Blood transfusion within 3 months
Diagnosis: microscopy
No details CYP2D6
Interventions • Chloroquine 3 days + primaquine 7 days (1 mg/kg/day).• Chloroquine 3 days + primaquine 14 days (0.5 mg/kg/day).• Dihydroartemisinin-piperaquine 3 days + primaquine 7 days (1 mg/kg/day).• Dihydroartemisinin-piperaquine 3 days + primaquine 14 days (0.5 mg/kg/day).
Supervised treatment.
Not specified whether primaquine given concurrently with chloroquine/dihydroartemisinin-piper-
aquine.
Outcomes • P vivax recurrence• Adverse events
Follow-up: 3 months, 4 months, 6 months, 8 months, 1 year
Notes Location: Thailand
Setting: Clinics along the Thailand-Myanmar border
Source of funding: The Wellcome Trust
Authors were contacted and provided 3-month and 6-month recurrence data for Analysis 4.3 and
Analysis 4.4
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomization was computer generated in blocks of 20”
Chu 2019 THA 
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Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Quote: “open 2-way randomized controlled trial”
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label and no mention of blood smear blinding
Incomplete outcome data
(attrition bias)
All outcomes
Unclear risk Overall, 40% leR the study before the end of 1-year follow-up. 4% of enrolled
participants did not receive blood-stage treatment and were not included in
any analyses. A further 20% had leR the study at 6 months and another 17% af-
ter 1 year. No imputations were used to account for participants that leR the
study early. However, dropouts were balanced between groups and reasons
for leaving the study were provided.
Selective reporting (re-
porting bias)
Low risk NCT record (NCT01640574) reports little information on outcomes, however all
are reported in the study
Other bias Low risk We did not detect any other sources of bias.
Chu 2019 THA  (Continued)
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Methods RCT
March 2006 to August 2008
Participants 360 participants
Inclusion criteria
• Microscopy-confirmed diagnosis of monoinfection with P vivax between 250 and 100,000 asexual par-
asites/mL (determined by microscopic examination of thick and thin peripheral blood smears).• Fever defined as axillary temperature 37.5 °C or history of fever, or both.• > 1 year old.
Exclusion criteria
• Pregnant and lactating women.• Patients with chronic illnesses.• Patients with symptoms of severe malaria.• Patients with G6PD deficiency.
Diagnosis: light microscopy.
Parasite genotyping with PCR also performed - 5 microsatellite loci used to determine whether homol-
ogous relapse.
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/day 7 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/day for 14 days.
Durand 2014 PER 
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(Additional arm of chloroquine + primaquine 0.5 mg/kg/day for 5 days excluded as total dose 150 mg,
which was less than standard treatment.)
Supervised.
Primaquine administered concurrently with chloroquine.
Outcomes • Relapse between days 35 and 210• Relapses (homologous only)
Follow-up: 210 days
Notes Location: Peru
Setting: Padre Cocha and the San Juan Health Centers and Santa Clara Health Center The periphery of
the city of Iquitos, which is located on the river bank of the Amazon River and is the largest city in the
Peruvian rainforest.
Funding: the US Department of Defense Global Emerging Infections Surveillance and Response Sys-
tem (DoD-GEIS), the National Institute of Health of Peru, and the Pan-American Health Organization/US
Agency for International Development (PAHO-USAID) Americas Malaria Initiative/Amazonic Network of
Antimalarial Drug Resistance, AMI/RAVREDA project.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated block randomization table.
Allocation concealment
(selection bias)
Low risk The treatment allocation for each participant was placed in a sealed envelope,
kept in an orderly manner, and opened only at the time of enrolment of a new
participant to prevent selection bias by study physicians.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label – no mention of blood smear blinding.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk 8% to 10% loss following randomization, but all accounted for.
Selective reporting (re-
porting bias)
Low risk Study protocol registered. Unable to find outcomes in protocol, but expected
outcomes were reported on.
Other bias Low risk We did not detect any other sources of bias.
Durand 2014 PER  (Continued)
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September 2004 to July 2006
Participants 129 Afghan refugees
Inclusion criteria
• Patients diagnosed with P vivax parasitaemia at study basic health units (BHUs).• Patients over 3 years of age.• Patient permanently resident in the village.
Exclusion criteria
• Pregnancy or lactation.• Severe clinical anaemia (7 g/dL).• P falciparum or P vivax (mixed infections), or both.• Intake of any antimalarial drug in the 2 weeks prior to consultation.• Patients unavailable for the duration of follow-up (11 months).• Patients with concomitant infections or disease likely to mask treatment response.
Diagnosis: microscopy
Interventions • Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.75 mg/kg once weekly for 8
weeks.• Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.5 mg/kg/day for 14 days.
(Additional arm chloroquine + weekly placebo not included).
Supervised.
Not specified whether primaquine given concurrently with chloroquine.
Outcomes • P vivax malaria relapse• The number of subsequent episodes and anaemia rates during and up to 2 weeks post-treatment as
well as any notable adverse events
Follow-up: 9 months (11 months participation: 8 weeks treatment + 9 months follow-up)
Notes Location: Pakistan
Setting: Adizai, Baghicha, and Khagan villages, close to Peshawar, Northwest Frontier Province, Pak-
istan where Afghan refugees have been resident for more than 20 years
Funding: UNDP/World Bank/WHO Special Program for Research in Tropical Diseases; Gates Malaria
Partnership)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Two randomization methods were used. In Baghicha and Khagan villages, par-
ticipants were randomized by household, whereas in Adizai, randomization
was at the individual level. Randomization lists for each village were generat-
ed using a random number list (MS Excel, Microsoft Corp, Seattle, USA) by staE
not involved in patient recruitment. Participants were randomized on enrol-
ment by study staE in the BHUs based on house number or sequential patient
numbers, depending on the study site.
Allocation concealment
(selection bias)
High risk Participants were randomized on enrolment by study staE in the BHUs based
on house number or sequential patient numbers, depending on the study site.
Leslie 2008 PAK  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Blood slides were double-read by 2 microscopists working independently, who
were blinded to the other's result.
Incomplete outcome data
(attrition bias)
All outcomes
High risk Higher loss to follow-up in intervention group (6% to 8% versus 1% to 1.8%).
Selective reporting (re-
porting bias)
Low risk Trial protocol available, all planned outcomes reported on.
Other bias Low risk We did not detect any other sources of bias.
Leslie 2008 PAK  (Continued)
 
 
Study characteristics
Methods RCT
Participants 358 participants
Inclusion criteria
• Patients of either sex.• Aged between 18 and 65 years.• Body weight > 40 kg.• Microscopically confirmed P vivax malaria with ≥ 1000 asexual parasites/µL of blood.• Axillary temperature ≥ 37.5°C (≥ 99.5°F).• Presence of at least 5 of the following signs and symptoms of uncomplicated malaria: chills, nausea,
vomiting, headache, malaise, diarrhoea, anorexia, abdominal cramps, myalgia, and arthralgia.
Exclusion criteria
• Mixed malarial infections.• Severe or complicated malaria (as defined by the WHO).• G6PD deficiency.• Any other significant concomitant illness.• Patients with history of dark urine or significant haemoglobinuria related to previous primaquine
treatment or those with history of methaemoglobinaemia.• Patients with protracted vomiting and oliguria.• Those with underlying condition compromising bone marrow function or having a tendency to gran-
ulocytopenia.• Patients taking cardioactive drug or potentially haemolytic drugs or drugs that could interact with
study drugs.• Patients having history of hypersensitivity to any of the study-related drugs.• Those on another investigational drug.• History/presence of substance abuse.• Pregnant or lactating women or women of childbearing potential not using medically accepted means
of birth control.
Pareek 2015 IND 
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Diagnosis: microscopy.
Interventions • Chloroquine (3-day course, dose not specified) + primaquine 30 mg sustained release 7 days.• Chloroquine (3-day course, dose not specified) + primaquine 15 mg 14 days.
(Additional arm of chloroquine + primaquine 15 mg sustained release for 14 days not included in re-
view).
Primaquine given following completion of chloroquine course.
Not supervised.
Outcomes • Relapse• Compliance• Safety
PCR genotyping done to see if true relapse (no details on genotyping method).
Follow-up: 5 months (6 months participation)
Notes Location: India.
Setting: multicentre, no details as to centres involved.
Funding: funded by drug manufacturer Ipca Laboratories Ltd. Anil Pareek and Nitin Chandurkar are the
employees of Ipca Laboratories Ltd who sponsored this trial.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization codes were generated using computer-generated block ran-
domization method.
Allocation concealment
(selection bias)
Low risk Patient-specific sealed boxes of medicine were provided to each study site.
(Sequentially numbered, sealed, opaque envelopes (from protocol)).
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Low risk Double-blind, double-dummy.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk No details as to whether microscopy was blinded or whether there was double
reading of smears.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Loss to follow-up equal between groups. Relapses counted as discontinued
patients, but numbers provided so can be assessed.
Selective reporting (re-
porting bias)
High risk Compliance added as an outcome, but original outcomes also reported on.
Not clear why they have concluded that compliance increased with SR, as par-
ticipants had to take 3 sets of pills as did those who took dummy versions, so
all participants took 3 sets of drugs.
No measurement of levels of PQ (pharmacokinetics), although states that PQ
SR should have therapeutic concentration over 24 hours as part of the con-
cept.
Pareek 2015 IND  (Continued)
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PCR results are not well-detailed.
Other bias Unclear risk The study was sponsored by Ipca Laboratories Ltd, who manufactures the
drugs, and the principal investigators are employees of the company.
Pareek 2015 IND  (Continued)
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Methods RCT
August 2001 to February 2004
Participants 1159 participants enrolled.
Inclusion criteria
• Adult patients, male and female (18 years of age or older).• Peripheral blood smear diagnosis of P vivax.• Willing to undergo hospitalization for the entire duration of primaquine treatment.• Willing to provide informed consent.• Willing to undergo investigations and come for regular follow-up.• Normal G6PD.• Haemoglobin ≥ 10 g/dL.
Exclusion criteria
• Mixed infection with P falciparum.• Pregnancy and lactation.• Evidence of significant hepatic, renal, or cardiac disease as diagnosed by history, clinical examination,
and laboratory tests whenever necessary.• Any other condition that would interfere with patient’s participation in the study or compliance with
the treatment.
Diagnosis: microscopy.
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 7 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 14 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 15 mg/day 14 days.
(Additional no-primaquine arm not included in analysis).
Supervised treatment.
Primquine treatment commenced after chloroquine treatment (day 4).
Outcomes • Recurrence of vivax malaria• Safety
Follow-up: 6 months
The secondary outcome also included comparison of number of participants classified as relapse and
re-infection by the 3 methods to determine the concordance between the methods used and the genet-
ic diversity observed based on PCR sequencing method. The cases of recurrence were classified as re-
lapse or re-infection based on the 3 methods, the month of recurrence, and the 2 genotyping methods:
PCR-RFLP and PCR sequencing.
Notes Location: Mumbai, India.
Rajgor 2014 IND 
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
40
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Setting: inpatient assessment in Mumbai.
Funding: Indian Council of Medical Research.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A simple, computer-generated randomization scheme was used for the ran-
domization of participants into the 3 PQ regimen groups.
Allocation concealment
(selection bias)
High risk This was an open-label study, and no concealment of treatment allocation was
followed.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Although the study was not blinded in terms of treatment administration, the
person seeing the slides and carrying out other outcome assessments was
blinded to the treatment group by coding of the samples.
Incomplete outcome data
(attrition bias)
All outcomes
High risk High percentage of participants not completing 6 months' follow-up across all
groups. Minimal explanation for discontinuation of participants.
Selective reporting (re-
porting bias)
Unclear risk No registered protocol found - reported on expected outcomes of efficacy and
adverse events. Trial carried out 2001 to 2004 but not published until 2014.
Other bias Low risk We did not detect any other sources of bias.
Rajgor 2014 IND  (Continued)
 
 
Study characteristics
Methods RCT, open-label, pilot study
March 2017 to August 2017
Participants 50 participants enrolled.
Patients presenting to Kasturba Hospital, Manipal and Dr TMA Pai Hospital, Udupi, India
Inclusion criteria
• P vivax malaria monoinfection.• Age 18 years and over.• Fever > 37.5°C tympanic or oral, or a history of fever within previous 3 days.• Willing to give informed consent.
Exclusion criteria
• Pregnant or lactating, or both.• Patients with G6PD deficiency.• Mixed infection with P vivax and P falciparum.
Primaquine given after blood-stage treatment.
Saravu 2018 IND 
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Diagnosis: microscopy, but PCR also performed to genotype recurrences.
No details CYP2D6.
Interventions Blood-stage treatment: either CQ or ACT (artesunate with doxycycline or artemether-lumefantrine as
per the treating clinician’s judgement of severity).
• Primaquine 0.5 mg/kg/day for 14 days.• Primaquine 0.25 mg/kg/day for 14 days.
Drug therapy not supervised.
Outcomes 1. Recurrence.
(2. Primaquine level in the blood at 7 days)
Follow-up 6 months
Notes Location: Udupi district of Karnataka State, India
Setting: typical tropical climatic conditions. Malaria incidence throughout the year with peaks around
June to July. Urban and rural settings in catchment area.
Source of funding: seed Grant Award from Manipal McGill Center for Infectious Diseases
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization – 5 blocks of 10, randomization within each block done
by a lottery method.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label.
Incomplete outcome data
(attrition bias)
All outcomes
High risk High percentage of loss to follow-up by 6 months in both arms – results diffi-
cult to interpret.
Selective reporting (re-
porting bias)
Low risk Outcomes reported as per protocol.
Other bias Low risk Supported by a seed Grant Award from Manipal McGill Center for Infectious
Diseases, MAHE, Manipal.
Saravu 2018 IND  (Continued)
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Methods RCT
October 1998 to January 1999
Participants 60 participants enrolled.
Inclusion criteria
• Confirmed diagnosis of P vivax malaria (febrile and positive P vivax blood smear).
Exclusion criteria
• Patients who had received antimalarial medication in the 4 weeks prior to diagnosis.• Children under 5 years.• Patients with severe concomitant diseases.
No details about inclusion/exclusion of G6PD-deficient/pregnant/breastfeeding patients.
Diagnosis: microscopy.
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/day for 14 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/day for 7 days.
Directly observed therapy.
Primaquine given after chloroquine course.
Outcomes • Relapse• Adverse events
Follow-up: 60 days (total enrolment 60 days)
Notes Location: Peru.
Setting: patients treated at San Martín de Pangoa Hospital, Junín
Funding: US Naval Medical Research Institute Detachment.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details on allocation process.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Samples double-checked, but no details as to whether blinded.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Missing data accounted for, similar in each group.
Solari-Soto 2002 PER  (Continued)
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Selective reporting (re-
porting bias)
Unclear risk No details.
Other bias Low risk We did not detect any other sources of bias.
Solari-Soto 2002 PER  (Continued)
 
 
Study characteristics
Methods RCT, multicentre
July 2014 to November 2018
Participants 2336 participants were randomised.
Inclusion criteria
• Participant (or parent/guardian of children below age of consent) is willing and able to give written
informed consent to participate in the trial; verbal consent in the presence of a literate witness is
required for illiterate patients. In addition, written assent (or verbal assent in the presence of a literate
witness for illiterates) from children 12 to 17 years as per local practice.• Monoinfection with P vivax of any parasitaemia in countries that use chloroquine as blood schizonti-
cidal therapy. Mixed infections with P vivax and P falciparum can be enrolled in countries that use an
artemisinin combination therapy.• Diagnosis based on rapid diagnostic tests.• Over 6 months of age.• Weight 5 kg or greater.• Fever (axillary temperature 37.5°C) or history of fever in the last 48 hours.• Able (in the investigator's opinion) and willing to comply with the study requirements and follow-up.
Exclusion criteria
• Female participant who is pregnant, lactating, or planning pregnancy during the course of the study.• Inability to tolerate oral treatment.• Previous episode of haemolysis or severe haemoglobinuria following primaquine.• Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral
treatment - haemoglobin concentration less than 9 g/dL.• Known hypersensitivity or allergy to the study drugs.• Blood transfusion in last 90 days, since this can mask G6PD-deficient status.• A febrile condition due to diseases other than malaria (for example, measles, acute lower respiratory
tract infection, severe diarrhoea with dehydration).• Presence of any condition which in the judgement of the investigator would place the participant at
undue risk or interfere with the results of the study (for example, serious underlying cardiac, renal, or
hepatic disease; severe malnutrition; HIV/AIDS; or severe febrile condition other than malaria); co-ad-
ministration of other medication known to cause haemolysis or that could interfere with the assess-
ment of antimalarial regimens.• Currently taking medication known to interfere significantly with the pharmacokinetics of primaquine
and the schizonticidal study drugs.• Prior antimalarial medications in the previous 7 days.
Diagnosis: microscopy
Patients with G6PD deficiency were excluded from the randomised trial, but were enrolled into a par-
allel observational group and treated with chloroquine or dihydroartemisinin-piperaquine plus super-
vised primaquine (0.75 mg/kg) once a week for 8 weeks.
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No details CYP2D6 status.
Interventions • Standard blood schizonticidal therapy plus 7 days of supervised primaquine (7 mg/kg total dose) ad-
ministered once per day (1.0 mg/kg once daily) followed by 7 days of placebo.• Standard blood schizonticidal therapy plus 14 days of supervised primaquine (7 mg/kg total dose)
administered once per day (0.5 mg/kg).
(Additional arm Standard blood schizonticidal therapy plus 14 days placebo was not included in the re-
view; no primaquine was administered to participants in this arm).
Supervised treatment.
Primaquine and blood schizonticidal therapy given concurrently.
Standard blood schizonticidal therapy was chloroquine in Ethiopia, Afghanistan, and Vietnam and di-
hydroartemisinin-piperaquine in Indonesia, according to local guidelines
Outcomes • Recurrent P vivax parasitaemia• Adverse events• Anaemia
Follow-up: 28 days, 42 days, 3 months, 6 months, 1 year.
Notes Location: Afghanistan (Jalalabad, Laghman), Ethiopia (Arba Minch, Metahara), Indonesia (Hanura, Tan-
jung Leidong), and Vietnam (Dak O & Bu Gia Map, Krong Pa).
Setting: Two health-care clinics in each country.
Funding: UK Department for International Development, UK Medical Research Council, UK National In-
stitute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme and
the Bill & Melinda Gates Foundation.
Authors were contacted and provided 3-month and 6-month recurrence data presented in Appendix
3b.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomisation was done using STATA version 14.1.(StataCorp, Col-
lege Station, TX, USA), which generated blocks of 20 for each dosing band”.
Allocation concealment
(selection bias)
Low risk Quote: “The independent statistician who generated the randomisation list
and selected code letters for primaquine or placebo was not otherwise in-
volved in the conduct of the trial and did not visit any of the study sites. Iden-
tical primaquine and placebo tablets were produced by the same manufactur-
er”
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Low risk Quote: “Participants and all of the local study team were masked to treatment
assignments.”
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk 98.6% accuracy in expert quality control of microscopy malaria films: Quote:
"Microscopists were trained in study laboratory procedures on-site and con-
tinuous quality control was implemented at all sites. Approximately 10% of
slides, including all the slides from day 0, the day of recurrent parasitaemia,
and the 6-month follow-up visits were assessed periodically over the course of
the trial by expert malaria microscopists"
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Safety outcomes: Quote: “The Data and Safety Monitoring Board did a blinded
safety review every 6 months”
Incomplete outcome data
(attrition bias)
All outcomes
Unclear risk Available case analysis, attrition after one year was 32% (297/935) in 7-day pri-
maquine group and 29% (270/937) in 14-day primaquine group, reasons for
leaving the study early were reported.
Selective reporting (re-
porting bias)
Low risk Protocol and online trial registry were checked; all outcomes and sensitivity
analyses were reported.
Other bias Low risk We did not detect any other sources of bias.
Taylor 2019 MULTI  (Continued)
Abbreviations: ACT: artemisinin-based combination therapy; CQ: chloroquine; CYP2D6: cytochrome P450 2D6; G6PD: glucose-6-phosphate
dehydrogenase; PCR: polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PQ:
primaquine; RCT: randomized controlled trial; SE: standard error; SR: sustained release; WHO: World Health Organization.
 
 
Study characteristics
Methods RCT
March 2006 to August 2008
Participants 360 participants
Inclusion criteria
• Microscopy-confirmed diagnosis of monoinfection with P vivax between 250 and 100,000 asexual par-
asites/mL (determined by microscopic examination of thick and thin peripheral blood smears).• Fever defined as axillary temperature 37.5 °C or history of fever, or both.• > 1 year old.
Exclusion criteria
• Pregnant and lactating women.• Patients with chronic illnesses.• Patients with symptoms of severe malaria.• Patients with G6PD deficiency.
Diagnosis: light microscopy.
Parasite genotyping with PCR also performed - 5 microsatellite loci used to determine whether homol-
ogous relapse.
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/day 7 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/day for 14 days.
(Additional arm of chloroquine + primaquine 0.5 mg/kg/day for 5 days excluded as total dose 150 mg,
which was less than standard treatment.)
Supervised.
Primaquine administered concurrently with chloroquine.
Outcomes • Relapse between days 35 and 210• Relapses (homologous only)
Follow-up: 210 days
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Notes Location: Peru
Setting: Padre Cocha and the San Juan Health Centers and Santa Clara Health Center The periphery of
the city of Iquitos, which is located on the river bank of the Amazon River and is the largest city in the
Peruvian rainforest.
Funding: the US Department of Defense Global Emerging Infections Surveillance and Response Sys-
tem (DoD-GEIS), the National Institute of Health of Peru, and the Pan-American Health Organization/US
Agency for International Development (PAHO-USAID) Americas Malaria Initiative/Amazonic Network of
Antimalarial Drug Resistance, AMI/RAVREDA project.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated block randomization table.
Allocation concealment
(selection bias)
Low risk The treatment allocation for each participant was placed in a sealed envelope,
kept in an orderly manner, and opened only at the time of enrolment of a new
participant to prevent selection bias by study physicians.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label – no mention of blood smear blinding.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk 8% to 10% loss following randomization, but all accounted for.
Selective reporting (re-
porting bias)
Low risk Study protocol registered. Unable to find outcomes in protocol, but expected
outcomes were reported on.
Other bias Low risk We did not detect any other sources of bias.
Durand 2014 PER  (Continued)
 
 
Study characteristics
Methods RCT
September 2004 to July 2006
Participants 129 Afghan refugees
Inclusion criteria
• Patients diagnosed with P vivax parasitaemia at study basic health units (BHUs).• Patients over 3 years of age.• Patient permanently resident in the village.
Exclusion criteria
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• Pregnancy or lactation.• Severe clinical anaemia (7 g/dL).• P falciparum or P vivax (mixed infections), or both.• Intake of any antimalarial drug in the 2 weeks prior to consultation.• Patients unavailable for the duration of follow-up (11 months).• Patients with concomitant infections or disease likely to mask treatment response.
Diagnosis: microscopy
Interventions • Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.75 mg/kg once weekly for 8
weeks.• Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.5 mg/kg/day for 14 days.
(Additional arm chloroquine + weekly placebo not included).
Supervised.
Not specified whether primaquine given concurrently with chloroquine.
Outcomes • P vivax malaria relapse• The number of subsequent episodes and anaemia rates during and up to 2 weeks post-treatment as
well as any notable adverse events
Follow-up: 9 months (11 months participation: 8 weeks treatment + 9 months follow-up)
Notes Location: Pakistan
Setting: Adizai, Baghicha, and Khagan villages, close to Peshawar, Northwest Frontier Province, Pak-
istan where Afghan refugees have been resident for more than 20 years
Funding: UNDP/World Bank/WHO Special Program for Research in Tropical Diseases; Gates Malaria
Partnership)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Two randomization methods were used. In Baghicha and Khagan villages, par-
ticipants were randomized by household, whereas in Adizai, randomization
was at the individual level. Randomization lists for each village were generat-
ed using a random number list (MS Excel, Microsoft Corp, Seattle, USA) by staE
not involved in patient recruitment. Participants were randomized on enrol-
ment by study staE in the BHUs based on house number or sequential patient
numbers, depending on the study site.
Allocation concealment
(selection bias)
High risk Participants were randomized on enrolment by study staE in the BHUs based
on house number or sequential patient numbers, depending on the study site.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Blood slides were double-read by 2 microscopists working independently, who
were blinded to the other's result.
Incomplete outcome data
(attrition bias)
High risk Higher loss to follow-up in intervention group (6% to 8% versus 1% to 1.8%).
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All outcomes
Selective reporting (re-
porting bias)
Low risk Trial protocol available, all planned outcomes reported on.
Other bias Low risk We did not detect any other sources of bias.
Leslie 2008 PAK  (Continued)
 
 
Study characteristics
Methods RCT
Participants 358 participants
Inclusion criteria
• Patients of either sex.• Aged between 18 and 65 years.• Body weight > 40 kg.• Microscopically confirmed P vivax malaria with ≥ 1000 asexual parasites/µL of blood.• Axillary temperature ≥ 37.5°C (≥ 99.5°F).• Presence of at least 5 of the following signs and symptoms of uncomplicated malaria: chills, nausea,
vomiting, headache, malaise, diarrhoea, anorexia, abdominal cramps, myalgia, and arthralgia.
Exclusion criteria
• Mixed malarial infections.• Severe or complicated malaria (as defined by the WHO).• G6PD deficiency.• Any other significant concomitant illness.• Patients with history of dark urine or significant haemoglobinuria related to previous primaquine
treatment or those with history of methaemoglobinaemia.• Patients with protracted vomiting and oliguria.• Those with underlying condition compromising bone marrow function or having a tendency to gran-
ulocytopenia.• Patients taking cardioactive drug or potentially haemolytic drugs or drugs that could interact with
study drugs.• Patients having history of hypersensitivity to any of the study-related drugs.• Those on another investigational drug.• History/presence of substance abuse.• Pregnant or lactating women or women of childbearing potential not using medically accepted means
of birth control.
Diagnosis: microscopy.
Interventions • Chloroquine (3-day course, dose not specified) + primaquine 30 mg sustained release 7 days.• Chloroquine (3-day course, dose not specified) + primaquine 15 mg 14 days.
(Additional arm of chloroquine + primaquine 15 mg sustained release for 14 days not included in re-
view).
Primaquine given following completion of chloroquine course.
Not supervised.
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Outcomes • Relapse• Compliance• Safety
PCR genotyping done to see if true relapse (no details on genotyping method).
Follow-up: 5 months (6 months participation)
Notes Location: India.
Setting: multicentre, no details as to centres involved.
Funding: funded by drug manufacturer Ipca Laboratories Ltd. Anil Pareek and Nitin Chandurkar are the
employees of Ipca Laboratories Ltd who sponsored this trial.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization codes were generated using computer-generated block ran-
domization method.
Allocation concealment
(selection bias)
Low risk Patient-specific sealed boxes of medicine were provided to each study site.
(Sequentially numbered, sealed, opaque envelopes (from protocol)).
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Low risk Double-blind, double-dummy.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk No details as to whether microscopy was blinded or whether there was double
reading of smears.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Loss to follow-up equal between groups. Relapses counted as discontinued
patients, but numbers provided so can be assessed.
Selective reporting (re-
porting bias)
High risk Compliance added as an outcome, but original outcomes also reported on.
Not clear why they have concluded that compliance increased with SR, as par-
ticipants had to take 3 sets of pills as did those who took dummy versions, so
all participants took 3 sets of drugs.
No measurement of levels of PQ (pharmacokinetics), although states that PQ
SR should have therapeutic concentration over 24 hours as part of the con-
cept.
PCR results are not well-detailed.
Other bias Unclear risk The study was sponsored by Ipca Laboratories Ltd, who manufactures the
drugs, and the principal investigators are employees of the company.
Pareek 2015 IND  (Continued)
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Methods RCT
August 2001 to February 2004
Participants 1159 participants enrolled.
Inclusion criteria
• Adult patients, male and female (18 years of age or older).• Peripheral blood smear diagnosis of P vivax.• Willing to undergo hospitalization for the entire duration of primaquine treatment.• Willing to provide informed consent.• Willing to undergo investigations and come for regular follow-up.• Normal G6PD.• Haemoglobin ≥ 10 g/dL.
Exclusion criteria
• Mixed infection with P falciparum.• Pregnancy and lactation.• Evidence of significant hepatic, renal, or cardiac disease as diagnosed by history, clinical examination,
and laboratory tests whenever necessary.• Any other condition that would interfere with patient’s participation in the study or compliance with
the treatment.
Diagnosis: microscopy.
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 7 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 14 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 15 mg/day 14 days.
(Additional no-primaquine arm not included in analysis).
Supervised treatment.
Primquine treatment commenced after chloroquine treatment (day 4).
Outcomes • Recurrence of vivax malaria• Safety
Follow-up: 6 months
The secondary outcome also included comparison of number of participants classified as relapse and
re-infection by the 3 methods to determine the concordance between the methods used and the genet-
ic diversity observed based on PCR sequencing method. The cases of recurrence were classified as re-
lapse or re-infection based on the 3 methods, the month of recurrence, and the 2 genotyping methods:
PCR-RFLP and PCR sequencing.
Notes Location: Mumbai, India.
Setting: inpatient assessment in Mumbai.
Funding: Indian Council of Medical Research.
Risk of bias
Bias Authors' judgement Support for judgement
Rajgor 2014 IND  (Continued)
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Random sequence genera-
tion (selection bias)
Low risk A simple, computer-generated randomization scheme was used for the ran-
domization of participants into the 3 PQ regimen groups.
Allocation concealment
(selection bias)
High risk This was an open-label study, and no concealment of treatment allocation was
followed.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk Although the study was not blinded in terms of treatment administration, the
person seeing the slides and carrying out other outcome assessments was
blinded to the treatment group by coding of the samples.
Incomplete outcome data
(attrition bias)
All outcomes
High risk High percentage of participants not completing 6 months' follow-up across all
groups. Minimal explanation for discontinuation of participants.
Selective reporting (re-
porting bias)
Unclear risk No registered protocol found - reported on expected outcomes of efficacy and
adverse events. Trial carried out 2001 to 2004 but not published until 2014.
Other bias Low risk We did not detect any other sources of bias.
Rajgor 2014 IND  (Continued)
 
 
Study characteristics
Methods RCT, open-label, pilot study
March 2017 to August 2017
Participants 50 participants enrolled.
Patients presenting to Kasturba Hospital, Manipal and Dr TMA Pai Hospital, Udupi, India
Inclusion criteria
• P vivax malaria monoinfection.• Age 18 years and over.• Fever > 37.5°C tympanic or oral, or a history of fever within previous 3 days.• Willing to give informed consent.
Exclusion criteria
• Pregnant or lactating, or both.• Patients with G6PD deficiency.• Mixed infection with P vivax and P falciparum.
Primaquine given after blood-stage treatment.
Diagnosis: microscopy, but PCR also performed to genotype recurrences.
No details CYP2D6.
Interventions Blood-stage treatment: either CQ or ACT (artesunate with doxycycline or artemether-lumefantrine as
per the treating clinician’s judgement of severity).
Saravu 2018 IND 
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• Primaquine 0.5 mg/kg/day for 14 days.• Primaquine 0.25 mg/kg/day for 14 days.
Drug therapy not supervised.
Outcomes 1. Recurrence.
(2. Primaquine level in the blood at 7 days)
Follow-up 6 months
Notes Location: Udupi district of Karnataka State, India
Setting: typical tropical climatic conditions. Malaria incidence throughout the year with peaks around
June to July. Urban and rural settings in catchment area.
Source of funding: seed Grant Award from Manipal McGill Center for Infectious Diseases
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization – 5 blocks of 10, randomization within each block done
by a lottery method.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
High risk Open-label.
Incomplete outcome data
(attrition bias)
All outcomes
High risk High percentage of loss to follow-up by 6 months in both arms – results diffi-
cult to interpret.
Selective reporting (re-
porting bias)
Low risk Outcomes reported as per protocol.
Other bias Low risk Supported by a seed Grant Award from Manipal McGill Center for Infectious
Diseases, MAHE, Manipal.
Saravu 2018 IND  (Continued)
 
 
Study characteristics
Methods RCT
October 1998 to January 1999
Participants 60 participants enrolled.
Inclusion criteria
Solari-Soto 2002 PER 
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• Confirmed diagnosis of P vivax malaria (febrile and positive P vivax blood smear).
Exclusion criteria
• Patients who had received antimalarial medication in the 4 weeks prior to diagnosis.• Children under 5 years.• Patients with severe concomitant diseases.
No details about inclusion/exclusion of G6PD-deficient/pregnant/breastfeeding patients.
Diagnosis: microscopy.
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/day for 14 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/day for 7 days.
Directly observed therapy.
Primaquine given after chloroquine course.
Outcomes • Relapse• Adverse events
Follow-up: 60 days (total enrolment 60 days)
Notes Location: Peru.
Setting: patients treated at San Martín de Pangoa Hospital, Junín
Funding: US Naval Medical Research Institute Detachment.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details on allocation process.
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias)
All outcomes
Unclear risk Samples double-checked, but no details as to whether blinded.
Incomplete outcome data
(attrition bias)
All outcomes
Low risk Missing data accounted for, similar in each group.
Selective reporting (re-
porting bias)
Unclear risk No details.
Other bias Low risk We did not detect any other sources of bias.
Solari-Soto 2002 PER  (Continued)
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Study characteristics
Methods RCT, multicentre
July 2014 to November 2018
Participants 2336 participants were randomised.
Inclusion criteria
• Participant (or parent/guardian of children below age of consent) is willing and able to give written
informed consent to participate in the trial; verbal consent in the presence of a literate witness is
required for illiterate patients. In addition, written assent (or verbal assent in the presence of a literate
witness for illiterates) from children 12 to 17 years as per local practice.• Monoinfection with P vivax of any parasitaemia in countries that use chloroquine as blood schizonti-
cidal therapy. Mixed infections with P vivax and P falciparum can be enrolled in countries that use an
artemisinin combination therapy.• Diagnosis based on rapid diagnostic tests.• Over 6 months of age.• Weight 5 kg or greater.• Fever (axillary temperature 37.5°C) or history of fever in the last 48 hours.• Able (in the investigator's opinion) and willing to comply with the study requirements and follow-up.
Exclusion criteria
• Female participant who is pregnant, lactating, or planning pregnancy during the course of the study.• Inability to tolerate oral treatment.• Previous episode of haemolysis or severe haemoglobinuria following primaquine.• Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral
treatment - haemoglobin concentration less than 9 g/dL.• Known hypersensitivity or allergy to the study drugs.• Blood transfusion in last 90 days, since this can mask G6PD-deficient status.• A febrile condition due to diseases other than malaria (for example, measles, acute lower respiratory
tract infection, severe diarrhoea with dehydration).• Presence of any condition which in the judgement of the investigator would place the participant at
undue risk or interfere with the results of the study (for example, serious underlying cardiac, renal, or
hepatic disease; severe malnutrition; HIV/AIDS; or severe febrile condition other than malaria); co-ad-
ministration of other medication known to cause haemolysis or that could interfere with the assess-
ment of antimalarial regimens.• Currently taking medication known to interfere significantly with the pharmacokinetics of primaquine
and the schizonticidal study drugs.• Prior antimalarial medications in the previous 7 days.
Diagnosis: microscopy
Patients with G6PD deficiency were excluded from the randomised trial, but were enrolled into a par-
allel observational group and treated with chloroquine or dihydroartemisinin-piperaquine plus super-
vised primaquine (0.75 mg/kg) once a week for 8 weeks.
No details CYP2D6 status.
Interventions • Standard blood schizonticidal therapy plus 7 days of supervised primaquine (7 mg/kg total dose) ad-
ministered once per day (1.0 mg/kg once daily) followed by 7 days of placebo.• Standard blood schizonticidal therapy plus 14 days of supervised primaquine (7 mg/kg total dose)
administered once per day (0.5 mg/kg).
(Additional arm Standard blood schizonticidal therapy plus 14 days placebo was not included in the re-
view; no primaquine was administered to participants in this arm).
Taylor 2019 MULTI 
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Supervised treatment.
Primaquine and blood schizonticidal therapy given concurrently.
Standard blood schizonticidal therapy was chloroquine in Ethiopia, Afghanistan, and Vietnam and di-
hydroartemisinin-piperaquine in Indonesia, according to local guidelines
Outcomes • Recurrent P vivax parasitaemia• Adverse events• Anaemia
Follow-up: 28 days, 42 days, 3 months, 6 months, 1 year.
Notes Location: Afghanistan (Jalalabad, Laghman), Ethiopia (Arba Minch, Metahara), Indonesia (Hanura, Tan-
jung Leidong), and Vietnam (Dak O & Bu Gia Map, Krong Pa).
Setting: Two health-care clinics in each country.
Funding: UK Department for International Development, UK Medical Research Council, UK National In-
stitute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme and
the Bill & Melinda Gates Foundation.
Authors were contacted and provided 3-month and 6-month recurrence data presented in Appendix
3b.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Quote: “Randomisation was done using STATA version 14.1.(StataCorp, Col-
lege Station, TX, USA), which generated blocks of 20 for each dosing band”.
Allocation concealment
(selection bias)
Low risk Quote: “The independent statistician who generated the randomisation list
and selected code letters for primaquine or placebo was not otherwise in-
volved in the conduct of the trial and did not visit any of the study sites. Iden-
tical primaquine and placebo tablets were produced by the same manufactur-
er”
Blinding of participants
and personnel (perfor-
mance bias)
All outcomes
Low risk Quote: “Participants and all of the local study team were masked to treatment
assignments.”
Blinding of outcome as-
sessment (detection bias)
All outcomes
Low risk 98.6% accuracy in expert quality control of microscopy malaria films: Quote:
"Microscopists were trained in study laboratory procedures on-site and con-
tinuous quality control was implemented at all sites. Approximately 10% of
slides, including all the slides from day 0, the day of recurrent parasitaemia,
and the 6-month follow-up visits were assessed periodically over the course of
the trial by expert malaria microscopists"
Safety outcomes: Quote: “The Data and Safety Monitoring Board did a blinded
safety review every 6 months”
Incomplete outcome data
(attrition bias)
All outcomes
Unclear risk Available case analysis, attrition after one year was 32% (297/935) in 7-day pri-
maquine group and 29% (270/937) in 14-day primaquine group, reasons for
leaving the study early were reported.
Selective reporting (re-
porting bias)
Low risk Protocol and online trial registry were checked; all outcomes and sensitivity
analyses were reported.
Taylor 2019 MULTI  (Continued)
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Other bias Low risk We did not detect any other sources of bias.
Taylor 2019 MULTI  (Continued)
Abbreviations: ACT: artemisinin-based combination therapy; CQ: chloroquine; CYP2D6: cytochrome P450 2D6; G6PD: glucose-6-phosphate
dehydrogenase; PCR: polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PQ:
primaquine; RCT: randomized controlled trial; SE: standard error; SR: sustained release; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adak 2001 No PQ comparison group.
Alvarez 2006 Comparison regimens are of a lower total dose than the control (15 mg/day for 3 days or 7 days) –
shown to be inferior in Galappaththy 2013.
Alvarez Sanchez 2007 Low-dose, shorter regimens of PQ.
Betuela 2012 Only one treatment group received primaquine.
Chu 2017 Wrong outcomes: primary outcome of this analysis was the fractional haematocrit reduction up to
day 14 after enrolment.
Chu 2018 No primaquine comparison arm.
Clyde 1977 Not an RCT, observational single-arm trial.
Contacos 1974 Not an RCT.
da Silva 1984 Not properly randomized (randomized according to whether the end of the notes code is odd or
even), low-dose comparison PQ group.
Daher 2018 Wrong comparator: same dose primaquine in all treatment arms (two tablets of 15 mg PQ for 7, 8 or
9 days, total dose between 3.0 and 4.2 mg/kg).
Gogtay 1999 Low-dose 15 mg for shorter time period (5 days) – shown to be ineffective in Galappaththy 2013.
Goller 2007 Not an RCT – logistic regression using already-published RCTs and observational studies (not pri-
mary trial).
Hamid 2018 Wrong comparator: Artesunate and Sulphadoxine/pyrimethamine + concomitant versus delayed
14-day primaquine.
Kim 2012 Wrong comparator: low-dose for 5 days - shown to be ineffective in Galappaththy 2013.
Kimura 1996 Not an RCT.
Krudsood 2008 Artesunate only as blood-stage treatment (does not meet inclusion criteria) and follow-up only 28
days.
Ladeia-Andrade 2019 Wrong comparator: concomitant versus delayed regimen (chloroquine with primaquine 0.5 mg/kg
once a day, for seven days (total dose, 3.5mg/kg) versus chloroquine with primaquine introduced
on day 28
Leslie 2004 No PQ comparison group: supervised versus unsupervised therapy.
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Study Reason for exclusion
Leslie 2008b Duplicate of Leslie 2008 PAK; conference abstract title only for session at ASTMH 57th Annual Meet-
ing.
Maneeboonyang 2011 Not randomized, participants were sequentially allocated into either the directly observed thera-
py (DOT) group or the self-administered therapy (SAT) group. No PQ comparison group, supervised
versus non-supervised therapy.
Miller 1974 Not an RCT.
Moore 2018 Not an RCT
Pasaribu 2013 No PQ comparison group.
Pukrittayakamee 2000 No PQ comparison group.
Sabchareon 1981 No blood-stage antimalarial treatment used in primaquine comparison group according to inclu-
sion criteria.
Saint-Yves IF 1977 Presumptive treatment of 45 mg PQ given to all participants before randomization.
Takeuchi 2010 No PQ comparison group: supervised versus non-supervised therapy.
Villalobos-Salcedo 2000 Wrong comparator: lower dose of PQ in comparison group (total dose 150 mg) - shown to be inef-
fective in Galappaththy 2013.
Warrasak 2019 No primaquine comparison arm, ophthalmological outcomes.
Abbreviations: PQ: primaquine; RCT: randomized controlled trial.
 
Characteristics of ongoing studies [ordered by study ID]
 
Study name Evaluation of safety and efficacy of two primaquine dosing regimens for the radical treatment of
Plasmodium vivax malaria in Vanuatu and Solomon Islands
Methods RCT, open-label
Participants Children and adults aged 12 months to 60 years. Solomon Islands and Vanuatu.
Inclusion criteria
• Age 12 months to 60 years.• Melanesian background and living in local area.• Microscopically (based on field microscopy) or RDT-confirmed P vivax regardless of parasite den-
sity. Mixed infections (P falciparum-P vivax and P malariae-P vivax) can be included.
Exclusion criteria
• Any signs of severe malaria (see WHO definitions) including: impaired consciousness, respirato-
ry distress, severe anaemia ("Hb < 5"), multiple seizures, frequent vomiting/inability to swallow
tablets, prostration, jaundice, hypotension, abnormal bleeding, or hypoglycaemia.• Clinical evidence of non-malarial illness (such as pneumonia or otitis media).• Severe malnutrition (weight-for-age nutritional Z score < 60th percentile).• Permanent disability that prevents or impedes study participation.• Treatment with primaquine in the previous 14 days.
NCT01837992 
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• Residence or planned travel outside the study area during the follow-up period (precluding su-
pervised treatment and follow-up procedures).• Known or suspected pregnancy.• Currently breastfeeding.• A positive rapid test for G6PD deficiency (Binax or Carestart RDT).
Interventions 1. Primaquine dose of 0.5 mg/kg/day for 14 consecutive days and standard age-based dosage 3-
day course of artemether-lumefantrine
2. Primaquine dose of 0.25 mg/kg for 14 consecutive days and standard age-based dosage 3-day
course of artemether-lumefantrine
(3. Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the
standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent
parasitaemia or completion of 3 months follow-up)
Outcomes • Efficacy: numbers of P vivax relapses per person-years of follow-up (Time Frame: 12 months).
Total number of microscopically diagnosed (including both symptomatic and asymptomatic in-
fections), PCR-confirmed relapses with P vivax in participants in each treatment arm over the 3-
month follow-up period, expressed as number of relapses per person-years of follow-up.• Safety and toxicity: mild, moderate, and severe adverse events, haemolysis, methaemoglobi-
naemia.
Starting date May 2013
Contact information Dr Ivo Mueller; mueller@wehi.edu.au
Notes Estimated completion date May 2015. Contacted for results - no response.
Protocol available at clinicaltrials.gov/ct2/show/NCT01837992
NCT01837992  (Continued)
Abbreviations: G6PD: glucose-6-phosphate dehydrogenase; Hb: haemoglobin; PCR: polymerase chain reaction; RCT: randomized
controlled trial; RDT: rapid diagnostic test; WHO: World Health Organization.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   0.5 mg/kg/day 7 days versus standard 0.25 mg/kg/day 14 days
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.1 Recurrence by 6 to 7 months' fol-
low-up
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
1.2 Recurrence by 6 to 7 months' fol-
low-up (PCR-adjusted)
2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.3 Recurrence by 6 to 7 months sub-
grouped by geographical region
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
1.3.1 South America 2 397 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.26]
1.3.2 Asia 2 814 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.73, 1.94]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1.4 Recurrence by 6 to 7 months sub-
grouped by directly observed therapy
(DOT) versus non-DOT
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
1.4.1 DOT 3 1017 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.67, 1.43]
1.4.2 Non-DOT 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.04, 5.20]
1.5 Serious adverse events 5 1427 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
1.6 Adverse events that result in discon-
tinuation of treatment
5 1427 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.15, 7.38]
1.7 Adverse events during chloroquine
administration
1 779 Risk Ratio (M-H, Fixed, 95% CI) 9.40 [0.51, 174.01]
1.8 Adverse effects during primaquine
administration
2 1019 Risk Ratio (M-H, Fixed, 95% CI) 1.64 [0.75, 3.57]
1.9 Other adverse events 2 135 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.23, 1.36]
1.10 Anaemia or change in haemoglobin
status
1 240 Risk Ratio (M-H, Fixed, 95% CI) 3.00 [0.12, 72.91]
 
 
Analysis 1.1.   Comparison 1: 0.5 mg/kg/day 7 days versus standard 0.25
mg/kg/day 14 days, Outcome 1: Recurrence by 6 to 7 months' follow-up
Study or Subgroup
Abdon 2001 BRA (1)
Durand 2014 PER (2)
Pareek 2015 IND (3)
Rajgor 2014 IND (4)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 2.99, df = 3 (P = 0.39); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 7 days
Events
0
16
1
30
47
Total
39
156
99
298
592
0.25mg/kg/day PQ 14 days
Events
2
22
2
26
52
Total
40
162
95
322
619
Weight
4.8%
42.2%
4.0%
48.9%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.20 [0.01 , 4.14]
0.76 [0.41 , 1.38]
0.48 [0.04 , 5.20]
1.25 [0.76 , 2.06]
0.96 [0.66 , 1.39]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
Footnotes
(1) Follow up 180 days (6 months)
(2) Follow up 210 days (7 months)
(3) Follow up 6 months. Primaquine 30mg sustained release preparation used.
(4) 6 months follow up
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Analysis 1.2.   Comparison 1: 0.5 mg/kg/day 7 days versus standard 0.25 mg/kg/
day 14 days, Outcome 2: Recurrence by 6 to 7 months' follow-up (PCR-adjusted)
Study or Subgroup
Durand 2014 PER (1)
Rajgor 2014 IND (2)
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 7 days
Events
8
12
Total
156
298
0.25mg/kg/day PQ 14 days
Events
12
5
Total
162
322
Risk Ratio
M-H, Fixed, 95% CI
0.69 [0.29 , 1.65]
2.59 [0.92 , 7.27]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
Footnotes
(1) Follow up 210 days (7 months)
(2) Follow up 6 months
 
 
Analysis 1.3.   Comparison 1: 0.5 mg/kg/day 7 days versus standard 0.25 mg/kg/day
14 days, Outcome 3: Recurrence by 6 to 7 months subgrouped by geographical region
Study or Subgroup
1.3.1 South America
Abdon 2001 BRA
Durand 2014 PER
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.70, df = 1 (P = 0.40); I² = 0%
Test for overall effect: Z = 1.19 (P = 0.23)
1.3.2 Asia
Pareek 2015 IND
Rajgor 2014 IND
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.59, df = 1 (P = 0.44); I² = 0%
Test for overall effect: Z = 0.69 (P = 0.49)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 2.99, df = 3 (P = 0.39); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi² = 1.86, df = 1 (P = 0.17), I² = 46.1%
0.5mg/kg/day PQ 7 days
Events
0
16
16
1
30
31
47
Total
39
156
195
99
298
397
592
0.25mg/kg/day PQ 14 days
Events
2
22
24
2
26
28
52
Total
40
162
202
95
322
417
619
Weight
4.8%
42.2%
47.1%
4.0%
48.9%
52.9%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.20 [0.01 , 4.14]
0.76 [0.41 , 1.38]
0.70 [0.39 , 1.26]
0.48 [0.04 , 5.20]
1.25 [0.76 , 2.06]
1.19 [0.73 , 1.94]
0.96 [0.66 , 1.39]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ Favours 0.25mg/kg/day PQ
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Analysis 1.4.   Comparison 1: 0.5 mg/kg/day 7 days versus standard 0.25 mg/kg/day 14 days, Outcome
4: Recurrence by 6 to 7 months subgrouped by directly observed therapy (DOT) versus non-DOT
Study or Subgroup
1.4.1 DOT
Abdon 2001 BRA
Durand 2014 PER
Rajgor 2014 IND
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 2.64, df = 2 (P = 0.27); I² = 24%
Test for overall effect: Z = 0.12 (P = 0.91)
1.4.2 Non-DOT
Pareek 2015 IND
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.60 (P = 0.55)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 2.99, df = 3 (P = 0.39); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)
Test for subgroup differences: Chi² = 0.33, df = 1 (P = 0.56), I² = 0%
0.5 mg/kg/day PQ 7 days
Events
0
16
30
46
1
1
47
Total
39
156
298
493
99
99
592
0.25 mg/kg/day PQ 14 days
Events
2
22
26
50
2
2
52
Total
40
162
322
524
95
95
619
Weight
4.8%
42.2%
48.9%
96.0%
4.0%
4.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.20 [0.01 , 4.14]
0.76 [0.41 , 1.38]
1.25 [0.76 , 2.06]
0.98 [0.67 , 1.43]
0.48 [0.04 , 5.20]
0.48 [0.04 , 5.20]
0.96 [0.66 , 1.39]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ Favours 0.25mg/kg/day PQ
 
 
Analysis 1.5.   Comparison 1: 0.5 mg/kg/day 7 days versus standard
0.25 mg/kg/day 14 days, Outcome 5: Serious adverse events
Study or Subgroup
Abdon 2001 BRA
Durand 2014 PER
Pareek 2015 IND (1)
Rajgor 2014 IND (2)
Solari-Soto 2002 PER
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Not applicable
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 7 days
Events
0
0
0
0
0
0
Total
40
156
99
381
28
704
0.25mg/kg/day PQ 14 days
Events
0
0
0
0
0
0
Total
40
162
95
398
28
723
Weight
Risk Ratio
M-H, Fixed, 95% CI
Not estimable
Not estimable
Not estimable
Not estimable
Not estimable
Not estimable
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
Footnotes
(1) Primaquine 30mg sustained release preparation used.
(2) 6 months follow up
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Analysis 1.6.   Comparison 1: 0.5 mg/kg/day 7 days versus standard 0.25 mg/kg/
day 14 days, Outcome 6: Adverse events that result in discontinuation of treatment
Study or Subgroup
Abdon 2001 BRA
Durand 2014 PER
Pareek 2015 IND (1)
Rajgor 2014 IND
Solari-Soto 2002 PER
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 7 days
Events
0
0
0
2
0
2
Total
40
156
99
381
28
704
0.25mg/kg/day PQ 14 days
Events
0
0
0
2
0
2
Total
40
162
95
398
28
723
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
Not estimable
Not estimable
Not estimable
1.04 [0.15 , 7.38]
Not estimable
1.04 [0.15 , 7.38]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
Footnotes
(1) Primaquine 30mg sustained release preparation used.
 
 
Analysis 1.7.   Comparison 1: 0.5 mg/kg/day 7 days versus standard 0.25 mg/
kg/day 14 days, Outcome 7: Adverse events during chloroquine administration
Study or Subgroup
Rajgor 2014 IND
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.50 (P = 0.13)
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 7 days
Events
4
4
Total
381
381
0.25mg/kg/day PQ 14 days
Events
0
0
Total
398
398
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
9.40 [0.51 , 174.01]
9.40 [0.51 , 174.01]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 1.8.   Comparison 1: 0.5 mg/kg/day 7 days versus standard 0.25 mg/
kg/day 14 days, Outcome 8: Adverse e@ects during primaquine administration
Study or Subgroup
Pareek 2015 IND (1)
Rajgor 2014 IND
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.48, df = 1 (P = 0.49); I² = 0%
Test for overall effect: Z = 1.25 (P = 0.21)
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 7 days
Events
6
10
16
Total
120
381
501
0.25mg/kg/day PQ 14 days
Events
5
5
10
Total
120
398
518
Weight
50.6%
49.4%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
1.20 [0.38 , 3.83]
2.09 [0.72 , 6.06]
1.64 [0.75 , 3.57]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
Footnotes
(1) Primaquine 30mg sustained release preparation used.
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Analysis 1.9.   Comparison 1: 0.5 mg/kg/day 7 days versus standard
0.25 mg/kg/day 14 days, Outcome 9: Other adverse events
Study or Subgroup
Abdon 2001 BRA
Solari-Soto 2002 PER
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.5 mg/kg/day PQ 7 days
Events
6
0
6
Total
39
28
67
0.25 mg/kg/day PQ 14 days
Events
11
0
11
Total
40
28
68
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.56 [0.23 , 1.36]
Not estimable
0.56 [0.23 , 1.36]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5 mg/kg/day PQ 7 days Favours 0.25 mg/kg/day PQ 14 days
 
 
Analysis 1.10.   Comparison 1: 0.5 mg/kg/day 7 days versus standard 0.25 mg/
kg/day 14 days, Outcome 10: Anaemia or change in haemoglobin status
Study or Subgroup
Pareek 2015 IND (1)
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 7 days
Events
1
1
Total
120
120
0.25mg/kg/day PQ 14 days
Events
0
0
Total
120
120
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
3.00 [0.12 , 72.91]
3.00 [0.12 , 72.91]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 7 days Favours 0.25mg/kg/day PQ 14 days
Footnotes
(1) Primaquine 30mg sustained release preparation used.
 
 
Comparison 2.   High-standard 0.5 mg/kg/day 14 days versus standard 0.25 mg/kg/day 14 days
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
2.1 Recurrence by 6 months' follow-up 2 677 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.49, 1.43]
2.1.1 6 months (chloroquine blood-stage
treatment)
1 639 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.47, 1.43]
2.1.2 6 months (chloroquine or ACT
blood-stage treatment)
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.17, 7.09]
2.2 Recurrence by 6 months' follow-up
(PCR-adjusted)
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.3 Serious adverse events 1 778 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
2.4 Adverse events that result in discon-
tinuation of treatment
1 778 Risk Ratio (M-H, Fixed, 95% CI) 4.19 [0.90, 19.60]
2.5 Other adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.5.1 AEs during chloroquine treatment 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2.5.2 AEs during primaquine treatment 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Analysis 2.1.   Comparison 2: High-standard 0.5 mg/kg/day 14 days versus
standard 0.25 mg/kg/day 14 days, Outcome 1: Recurrence by 6 months' follow-up
Study or Subgroup
2.1.1 6 months (chloroquine blood-stage treatment)
Rajgor 2014 IND (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.70 (P = 0.48)
2.1.2 6 months (chloroquine or ACT blood-stage treatment)
Saravu 2018 IND (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.11 (P = 0.91)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.09, df = 1 (P = 0.76); I² = 0%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Chi² = 0.09, df = 1 (P = 0.76), I² = 0%
0.5mg/kg/day PQ 14 days
Events
21
21
2
2
23
Total
317
317
18
18
335
0.25mg/kg/day PQ 14 days
Events
26
26
2
2
28
Total
322
322
20
20
342
Weight
93.2%
93.2%
6.8%
6.8%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.82 [0.47 , 1.43]
0.82 [0.47 , 1.43]
1.11 [0.17 , 7.09]
1.11 [0.17 , 7.09]
0.84 [0.49 , 1.43]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
Footnotes
(1) Chloroquine used for blood stage treatment, treatment supervised
(2) Blood stage treatment is either chloroquine or an ACT, treatment unsupervised
 
 
Analysis 2.2.   Comparison 2: High-standard 0.5 mg/kg/day 14 days versus standard
0.25 mg/kg/day 14 days, Outcome 2: Recurrence by 6 months' follow-up (PCR-adjusted)
Study or Subgroup
Rajgor 2014 IND
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 14 days
Events
9
Total
317
0.25mg/kg/day PQ 14 days
Events
5
Total
322
Risk Ratio
M-H, Fixed, 95% CI
1.83 [0.62 , 5.40]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.3.   Comparison 2: High-standard 0.5 mg/kg/day 14 days versus
standard 0.25 mg/kg/day 14 days, Outcome 3: Serious adverse events
Study or Subgroup
Rajgor 2014 IND
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Not applicable
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 14 days
Events
0
0
Total
380
380
0.25mg/kg/day PQ 14 days
Events
0
0
Total
398
398
Weight
Risk Ratio
M-H, Fixed, 95% CI
Not estimable
Not estimable
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
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Analysis 2.4.   Comparison 2: High-standard 0.5 mg/kg/day 14 days versus standard 0.25
mg/kg/day 14 days, Outcome 4: Adverse events that result in discontinuation of treatment
Study or Subgroup
Rajgor 2014 IND
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.82 (P = 0.07)
Test for subgroup differences: Not applicable
0.5mg/kg/day PQ 14 days
Events
8
8
Total
380
380
0.25mg/kg/day PQ 14 days
Events
2
2
Total
398
398
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
4.19 [0.90 , 19.60]
4.19 [0.90 , 19.60]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.5.   Comparison 2: High-standard 0.5 mg/kg/day 14 days versus
standard 0.25 mg/kg/day 14 days, Outcome 5: Other adverse events
Study or Subgroup
2.5.1 AEs during chloroquine treatment
Rajgor 2014 IND
2.5.2 AEs during primaquine treatment
Rajgor 2014 IND
0.5mg/kg/day PQ 14 days
Events
4
13
Total
380
380
0.25mg/kg/day PQ 14 days
Events
0
5
Total
398
398
Risk Ratio
M-H, Fixed, 95% CI
9.43 [0.51 , 174.47]
2.72 [0.98 , 7.57]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.5mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
 
 
Comparison 3.   0.75 mg/kg/week 8 weeks versus high-standard 0.5 mg/kg/day 14 days
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
3.1 Recurrence 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1.1 5 months 1 129 Risk Ratio (M-H, Fixed, 95% CI) 5.23 [0.28, 99.15]
3.1.2 8 months 1 126 Risk Ratio (M-H, Fixed, 95% CI) 7.00 [0.38, 127.32]
3.1.3 11 months 1 122 Risk Ratio (M-H, Fixed, 95% CI) 3.18 [0.37, 27.60]
3.2 Serious adverse events 1 129 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.3 Anaemia (haemoglobin < 7 g/
dL)
1 129 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
3.4 Other adverse events 1 129 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Analysis 3.1.   Comparison 3: 0.75 mg/kg/week 8 weeks versus
high-standard 0.5 mg/kg/day 14 days, Outcome 1: Recurrence
Study or Subgroup
3.1.1 5 months
Leslie 2008 PAK
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.10 (P = 0.27)
3.1.2 8 months
Leslie 2008 PAK
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.31 (P = 0.19)
3.1.3 11 months
Leslie 2008 PAK
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Test for subgroup differences: Chi² = 0.20, df = 2 (P = 0.91), I² = 0%
0.75mg/kg PQ weekly 8wks
Events
3
3
4
4
4
4
Total
74
74
71
71
68
68
0.5mg/kg/day PQ 14 days
Events
0
0
0
0
1
1
Total
55
55
55
55
54
54
Weight
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
5.23 [0.28 , 99.15]
5.23 [0.28 , 99.15]
7.00 [0.38 , 127.32]
7.00 [0.38 , 127.32]
3.18 [0.37 , 27.60]
3.18 [0.37 , 27.60]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.75mg/kg PQ weekly 8wks Favours 0.5mg/kg/day PQ 14 days
 
 
Analysis 3.2.   Comparison 3: 0.75 mg/kg/week 8 weeks versus high-
standard 0.5 mg/kg/day 14 days, Outcome 2: Serious adverse events
Study or Subgroup
Leslie 2008 PAK
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Not applicable
Test for subgroup differences: Not applicable
0.75mg/kg PQ weekly 8wks
Events
0
0
Total
74
74
0.5mg/kg/day PQ 14 days
Events
0
0
Total
55
55
Weight
Risk Ratio
M-H, Fixed, 95% CI
Not estimable
Not estimable
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.75mg/kg PQ weekly 8wks Favours 0.5mg/kg/day PQ 14 days
 
 
Analysis 3.3.   Comparison 3: 0.75 mg/kg/week 8 weeks versus high-
standard 0.5 mg/kg/day 14 days, Outcome 3: Anaemia (haemoglobin < 7 g/dL)
Study or Subgroup
Leslie 2008 PAK
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Not applicable
Test for subgroup differences: Not applicable
0.75mg/kg PQ weekly 8wks
Events
0
0
Total
74
74
0.5mg/kg/day PQ 14 days
Events
0
0
Total
55
55
Weight
Risk Ratio
M-H, Fixed, 95% CI
Not estimable
Not estimable
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.75mg/kg PQ weekly 8wks Favours 0.5mg/kg/day PQ 14 days
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Analysis 3.4.   Comparison 3: 0.75 mg/kg/week 8 weeks versus high-
standard 0.5 mg/kg/day 14 days, Outcome 4: Other adverse events
Study or Subgroup
Leslie 2008 PAK
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Not applicable
Test for subgroup differences: Not applicable
0.75mg/kg PQ weekly 8wks
Events
0
0
Total
74
74
0.5mg/kg/day PQ 14 days
Events
0
0
Total
55
55
Weight
Risk Ratio
M-H, Fixed, 95% CI
Not estimable
Not estimable
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.75mg/kg PQ weekly 8wks Favours 0.5mg/kg/day PQ 14 days
 
 
Comparison 4.   1.0 mg/kg/day primaquine 7 days versus high-standard 0.5 mg/kg/day 14 days
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.1 Recurrence by 12 months'
follow-up
2 2526 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.82, 1.30]
4.1.1 Chloroquine blood-stage
treatment
2 1404 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.67, 1.22]
4.1.2 DHA-PPQ blood-stage
treatment
2 1122 Risk Ratio (M-H, Fixed, 95% CI) 1.24 [0.87, 1.77]
4.2 Recurrence by 12 months'
follow-up subgrouped by geo-
graphical region
2 2526 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.82, 1.29]
4.2.1 Afghanistan 1 348 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.44, 1.28]
4.2.2 Ethiopia 1 466 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.74, 2.30]
4.2.3 Indonesia 1 797 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.86, 2.03]
4.2.4 Thailand 1 654 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.57, 1.30]
4.2.5 Vietnam 1 261 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.43, 2.53]
4.3 Recurrence by 6 months'
follow-up
1 474 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.61, 1.97]
4.3.1 Chloroquine blood-stage
treatment
1 256 Risk Ratio (M-H, Fixed, 95% CI) 0.88 [0.42, 1.86]
4.3.2 DHA-PPQ blood-stage
treatment
1 218 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.60, 4.05]
4.4 Recurrence by 3 months'
follow-up
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.4.1 Chloroquine blood-stage
treatment
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
4.4.2 DHA-PPQ blood-stage
treatment
1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.5 P vivax parasitaemia 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.5.1 Day 28 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.5.2 Day 42 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
4.6 Serious adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.6.1 Up to 42 days follow-up 1 1872 Risk Ratio (M-H, Fixed, 95% CI) 12.03 [1.57, 92.30]
4.6.2 Up to 1 year follow-up 1 1872 Risk Ratio (M-H, Fixed, 95% CI) 3.61 [1.35, 9.68]
4.7 Adverse events that result-
ed in discontinuation of treat-
ment
2 2526 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [0.49, 12.87]
4.8 Other adverse events 2   Other data No numeric data
4.8.1 Up to day 14 1   Other data No numeric data
4.8.2 Chloroquine group, up to
day 42
1   Other data No numeric data
4.8.3 DHA-PPQ group, up to
day 42
1   Other data No numeric data
4.9 Anaemia 2 2440 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.62, 1.41]
4.9.1 Up to 3 days 1 1786 Risk Ratio (M-H, Fixed, 95% CI) 1.00 [0.38, 2.66]
4.9.2 Up to 42 days follow-up 1 654 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.58, 1.44]
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Analysis 4.1.   Comparison 4: 1.0 mg/kg/day primaquine 7 days versus high-
standard 0.5 mg/kg/day 14 days, Outcome 1: Recurrence by 12 months' follow-up
Study or Subgroup
4.1.1 Chloroquine blood-stage treatment
Chu 2019 THA (1)
Taylor 2019 MULTI (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.82, df = 1 (P = 0.37); I² = 0%
Test for overall effect: Z = 0.65 (P = 0.52)
4.1.2 DHA-PPQ blood-stage treatment
Chu 2019 THA (1)
Taylor 2019 MULTI (3)
Subtotal (95% CI)
Total events:
Heterogeneity: Chi² = 0.29, df = 1 (P = 0.59); I² = 0%
Test for overall effect: Z = 1.18 (P = 0.24)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 2.87, df = 3 (P = 0.41); I² = 0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi² = 1.75, df = 1 (P = 0.19), I² = 43.0%
1 mg/kg/day PQ 7 days
Events
20
54
74
17
44
61
135
Total
165
535
700
162
400
562
1262
0.5 mg/kg/day PQ 14 days
Events
27
55
82
16
33
49
131
Total
164
540
704
163
397
560
1264
Weight
20.7%
41.8%
62.5%
12.2%
25.3%
37.5%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.74 [0.43 , 1.26]
0.99 [0.69 , 1.41]
0.91 [0.67 , 1.22]
1.07 [0.56 , 2.04]
1.32 [0.86 , 2.03]
1.24 [0.87 , 1.77]
1.03 [0.82 , 1.30]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1 mg/kg/day PQ 7 days Favours 0.5 mg/kg/day PQ 14 days
Footnotes
(1) first P. vivax infection within 1 year
(2) first P. vivax recurrence, Afghanistan, Ethiopia, and Vietnam cohorts
(3) first P. vivax recurrence, Indonesia cohort
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Analysis 4.2.   Comparison 4: 1.0 mg/kg/day primaquine 7 days versus high-standard 0.5 mg/kg/
day 14 days, Outcome 2: Recurrence by 12 months' follow-up subgrouped by geographical region
Study or Subgroup
4.2.1 Afghanistan
Taylor 2019 MULTI (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
4.2.2 Ethiopia
Taylor 2019 MULTI (2)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
4.2.3 Indonesia
Taylor 2019 MULTI (3)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.28 (P = 0.20)
4.2.4 Thailand
Chu 2019 THA (4)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
4.2.5 Vietnam
Taylor 2019 MULTI (5)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.08 (P = 0.93)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 4.05, df = 4 (P = 0.40); I² = 1%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Chi² = 4.04, df = 4 (P = 0.40), I² = 1.1%
1 mg/kg/day PQ 7 days
Events
20
20
25
25
44
44
37
37
9
9
135
Total
173
173
234
234
400
400
327
327
128
128
1262
0.5 mg/kg/day PQ 14 days
Events
27
27
19
19
33
33
43
43
9
9
131
Total
175
175
232
232
397
397
327
327
133
133
1264
Weight
20.5%
20.5%
14.6%
14.6%
25.3%
25.3%
32.9%
32.9%
6.7%
6.7%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.75 [0.44 , 1.28]
0.75 [0.44 , 1.28]
1.30 [0.74 , 2.30]
1.30 [0.74 , 2.30]
1.32 [0.86 , 2.03]
1.32 [0.86 , 2.03]
0.86 [0.57 , 1.30]
0.86 [0.57 , 1.30]
1.04 [0.43 , 2.53]
1.04 [0.43 , 2.53]
1.03 [0.82 , 1.29]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1 mg/kg/day PQ 7 days Favours 0.5 mg/kg/day PQ 14 days
Footnotes
(1) first recurrent P. vivax parasitaemia, Afghanistan
(2) first recurrent P. vivax parasitaemia, Ethiopia
(3) first recurrent P. vivax parasitaemia, Indonesia
(4) first P. vivax infection within 1 year
(5) first recurrent P. vivax parasitaemia, Vietnam
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Analysis 4.3.   Comparison 4: 1.0 mg/kg/day primaquine 7 days versus high-
standard 0.5 mg/kg/day 14 days, Outcome 3: Recurrence by 6 months' follow-up
Study or Subgroup
4.3.1 Chloroquine blood-stage treatment
Chu 2019 THA
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
4.3.2 DHA-PPQ blood-stage treatment
Chu 2019 THA
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.90 (P = 0.37)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.84, df = 1 (P = 0.36); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.75)
Test for subgroup differences: Chi² = 0.84, df = 1 (P = 0.36), I² = 0%
1 mg/kg/day PQ 7 days
Events
12
12
11
11
23
Total
131
131
118
118
249
0.5 mg/kg/day PQ 14 days
Events
13
13
6
6
19
Total
125
125
100
100
225
Weight
67.2%
67.2%
32.8%
32.8%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.88 [0.42 , 1.86]
0.88 [0.42 , 1.86]
1.55 [0.60 , 4.05]
1.55 [0.60 , 4.05]
1.10 [0.61 , 1.97]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1 mg/kg/day PQ 7 days Favours 0.5 mg/kg/day PQ 14 days
 
 
Analysis 4.4.   Comparison 4: 1.0 mg/kg/day primaquine 7 days versus high-
standard 0.5 mg/kg/day 14 days, Outcome 4: Recurrence by 3 months' follow-up
Study or Subgroup
4.4.1 Chloroquine blood-stage treatment
Chu 2019 THA
4.4.2 DHA-PPQ blood-stage treatment
Chu 2019 THA
1 mg/kg/day PQ 7 days
Events
5
6
Total
144
125
0.5 mg/kg/day PQ 14 days
Events
7
4
Total
139
114
Risk Ratio
M-H, Fixed, 95% CI
0.69 [0.22 , 2.12]
1.37 [0.40 , 4.72]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1 mg/kg/day PQ 7 days Favours 0.5 mg/kg/day PQ 14 days
 
 
Analysis 4.5.   Comparison 4: 1.0 mg/kg/day primaquine 7 days versus
high-standard 0.5 mg/kg/day 14 days, Outcome 5: P vivax parasitaemia
Study or Subgroup
4.5.1 Day 28
Taylor 2019 MULTI
4.5.2 Day 42
Taylor 2019 MULTI
1 mg/kg/day PQ 7 days
Events
2
7
Total
935
935
0.5 mg/kg/day PQ 14 days
Events
3
7
Total
937
937
Risk Ratio
M-H, Fixed, 95% CI
0.67 [0.11 , 3.99]
1.00 [0.35 , 2.85]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1 mg/kg/day PQ 7 days Favours 0.5 mg/kg/day PQ 14 days
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Analysis 4.6.   Comparison 4: 1.0 mg/kg/day primaquine 7 days versus high-
standard 0.5 mg/kg/day 14 days, Outcome 6: Serious adverse events
Study or Subgroup
4.6.1 Up to 42 days follow-up
Taylor 2019 MULTI
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.39 (P = 0.02)
4.6.2 Up to 1 year follow-up
Taylor 2019 MULTI
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 2.55 (P = 0.01)
1 mg/kg/day PQ 7 days
Events
12
12
18
18
Total
935
935
935
935
0.5 mg/kg/day PQ 14 days
Events
1
1
5
5
Total
937
937
937
937
Weight
100.0%
100.0%
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
12.03 [1.57 , 92.30]
12.03 [1.57 , 92.30]
3.61 [1.35 , 9.68]
3.61 [1.35 , 9.68]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1 mg/kg/day PQ 7 days Favours 0.5 mg/kg/day PQ 14 days
 
 
Analysis 4.7.   Comparison 4: 1.0 mg/kg/day primaquine 7 days versus high-standard 0.5 mg/
kg/day 14 days, Outcome 7: Adverse events that resulted in discontinuation of treatment
Study or Subgroup
Chu 2019 THA (1)
Taylor 2019 MULTI
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.06, df = 1 (P = 0.81); I² = 0%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
1 mg/kg/day PQ 7 days
Events
3
2
5
Total
327
935
1262
0.5 mg/kg/day PQ 14 days
Events
1
1
2
Total
327
937
1264
Weight
50.0%
50.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
3.00 [0.31 , 28.69]
2.00 [0.18 , 22.07]
2.50 [0.49 , 12.87]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1 mg/kg/day PQ 7 days Favours 0.5 mg/kg/day PQ 14 days
Footnotes
(1) [table S7; note table S8 reports slightly different data]
 
 
Analysis 4.8.   Comparison 4: 1.0 mg/kg/day primaquine 7 days versus
high-standard 0.5 mg/kg/day 14 days, Outcome 8: Other adverse events
 
Other adverse events
Study 1.0 mg/kg/day for 7 days High-standard 0.5 mg/kg/day for 14 days
Up to day 14
Taylor 2019 MULTI 1819 events in 935 participants 1732 events in 937 participants
Chloroquine group, up to day 42
Chu 2019 THA 97 events in 165 participants 91 events in 164 participants
DHA-PPQ group, up to day 42
Chu 2019 THA 72 events in 162 participants 82 events in 163 participants
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Analysis 4.9.   Comparison 4: 1.0 mg/kg/day primaquine 7 days
versus high-standard 0.5 mg/kg/day 14 days, Outcome 9: Anaemia
Study or Subgroup
4.9.1 Up to 3 days
Taylor 2019 MULTI (1)
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
4.9.2 Up to 42 days follow-up
Chu 2019 THA
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 0.39 (P = 0.70)
Total (95% CI)
Total events:
Heterogeneity: Chi² = 0.03, df = 1 (P = 0.86); I² = 0%
Test for overall effect: Z = 0.34 (P = 0.73)
Test for subgroup differences: Chi² = 0.03, df = 1 (P = 0.86), I² = 0%
1 mg/kg/day PQ 7 days
Events
8
8
32
32
40
Total
891
891
327
327
1218
0.5 mg/kg/day PQ 14 days
Events
8
8
35
35
43
Total
895
895
327
327
1222
Weight
18.6%
18.6%
81.4%
81.4%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
1.00 [0.38 , 2.66]
1.00 [0.38 , 2.66]
0.91 [0.58 , 1.44]
0.91 [0.58 , 1.44]
0.93 [0.62 , 1.41]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1 mg/kg/day PQ 7 days Favours 0.5 mg/kg/day PQ 14 days
Footnotes
(1) percentage decrease in haemoglobin of more than 25% between enrolment and day 3
 
 
Comparison 5.   0.375 mg/kg/day primaquine for 14 days versus standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5.1 Recurrence by 6 months' follow-up 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
5.1.1 6 months' follow-up 1 73 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.01, 3.34]
5.1.2 12 months' follow-up 1 49 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.1.3 18 months' follow-up 1 38 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
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Analysis 5.1.   Comparison 5: 0.375 mg/kg/day primaquine for 14 days versus
standard 14-day regimen, Outcome 1: Recurrence by 6 months' follow-up
Study or Subgroup
5.1.1 6 months' follow-up
Bunnag 1994 THA
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
5.1.2 12 months' follow-up
Bunnag 1994 THA
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Not applicable
5.1.3 18 months' follow-up
Bunnag 1994 THA
Subtotal (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Not applicable
Test for subgroup differences: Not applicable
0.375mg/kg/day PQ 14 days
Events
0
0
0
0
0
0
Total
40
40
24
24
19
19
0.25mg/kg/day PQ 14 days
Events
2
2
0
0
0
0
Total
33
33
25
25
19
19
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
0.17 [0.01 , 3.34]
0.17 [0.01 , 3.34]
Not estimable
Not estimable
Not estimable
Not estimable
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 0.375mg/kg/day PQ 14 days Favours 0.25mg/kg/day PQ 14 days
 
 
Comparison 6.   1.17 mg/kg/day primaquine for 3 days versus standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
6.1 Recurrence by 4 months' follow-up 1 129 Risk Ratio (M-H, Fixed, 95% CI) 3.88 [2.11, 7.11]
 
 
Analysis 6.1.   Comparison 6: 1.17 mg/kg/day primaquine for 3 days versus
standard 14-day regimen, Outcome 1: Recurrence by 4 months' follow-up
Study or Subgroup
Carmona-Fonseca 2009 COL (1)
Total (95% CI)
Total events:
Heterogeneity: Not applicable
Test for overall effect: Z = 4.37 (P < 0.0001)
Test for subgroup differences: Not applicable
1.17mg/kg/day PQ 3 days
Events
37
37
Total
63
63
0.25mg/kg/day PQ 14 days
Events
10
10
Total
66
66
Weight
100.0%
100.0%
Risk Ratio
M-H, Fixed, 95% CI
3.88 [2.11 , 7.11]
3.88 [2.11 , 7.11]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours 1.17mg/kg/day PQ 3 days Favours 0.25mg/kg/day PQ 14 days
Footnotes
(1) Follow up 120 days (4 months)
 
 
A D D I T I O N A L   T A B L E S
 
Objective Intervention Control
Table 1.   Data extraction: grouping of comparisons to address the review's objectives 
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Are higher doses (0.5
mg/kg/day or 30 mg/
day primaquine for 14
days) more effective in
all areas, or only in areas
where they are standard
treatment (East Asia and
Oceania)?
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg/day (adult dose 30
mg) for 14 days (total dose 420 mg).
Both intervention and control groups
must have received the same treatment
for the blood-borne stage of infection,
that is, either CQ or ACT.
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg).
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Are shorter, higher-dose
regimens of primaquine
over 7 days as effective
as treatment over 14
days (is the total dose
rather than the length of
treatment the important
factor)?
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg/day (adult dose 30
mg) for 7 days (total dose 210 mg) or 1
mg/kg/day (adult dose 60 mg) for 7 days
(total dose 420 mg).
Both intervention and control groups
must have received the same treatment
for the blood-borne stage of infection,
that is, either CQ or ACT.
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg) or high-standard 14-day course primaquine (0.5 mg/
kg/day, adult dose 30 mg, total dose 420 mg).
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Are weekly dosing regi-
mens (0.75 mg/kg/week
or 45 mg/week for 8
weeks) as effective?
Blood-stage antimalarial drug with pri-
maquine 0.75/kg (45 mg) per week for 8
weeks (total dose 360 mg)
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg) or high-standard 14-day course primaquine (0.5 mg/
kg/day, adult dose 30 mg, total dose 420 mg).
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Table 1.   Data extraction: grouping of comparisons to address the review's objectives  (Continued)
Abbreviations: ACT = artemisinin-based combination therapy; CQ = chloroquine.
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategies
 
PubMed MEDLINE
1 primaquine [Title/Abstract]
2 "Primaquine"[Mesh]
3 1 or 2
4 "plasmodium vivax" [Title/Abstract]
5 "Plasmodium vivax"[Mesh]
6 "vivax malaria " [Title/Abstract]
7 "Malaria, Vivax"[Mesh]
8 4 or 5 or 6
9 3 and 8
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10 "Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publication Type]
11 randomized or placebo [Title/Abstract]
12 randomly or trial or groups [Title/Abstract]
13 "drug therapy" [Subheading]
14 10 or 11 or 12 or 13
15 9 and 14
  (Continued)
 
Cochrane Library
Issue 9 2019
ID Search
#1 primaquine: ti,ab,kw: (Word variations have been searched)
#2 MeSH descriptor: [Primaquine] explode all trees
#3 #1 or #2
#4 "plasmodium vivax": ti, ab,kw (Word variations have been searched)
#5 MeSH descriptor: [Malaria, Vivax] explode all trees
#6 MeSH descriptor: [Plasmodium vivax ] explode all trees
#7 #4 or #5 or #6
#8 #3 and #7
Embase
1947-Present, updated daily
--------------------------------------------------------------------------------
1 "primaquine".mp.
2 primaquine/
3 1 or 2
4 plasmodium vivax.mp. or Plasmodium vivax/
5 malaria vivax.mp. or Plasmodium vivax malaria/
6 4 or 5 or 6
7 controlled clinical trial.mp. or Controlled Clinical Trial/
8 randomized controlled trial.mp. or Randomized Controlled Trial/
9 (randomized or placebo or double-blind* or single-blind*).mp.
10 randomization/
11 crossover procedure/
12 7 or 8 or 9 or 10 or 11
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13 3 and 6 and 12
LILACS
Search on: primaquine [Words] and malaria vivax or plasmodium vivax [Words]
ClinicalTrials.gov and WHO ICTRP
primaquine and vivax
Appendix 2. Safety additional data
High-standard 14-day regimen versus standard 14-day regimen
 
Study High-standard 14-day regimen Standard 14-day regimen
Rajgor 2014 IND Total population = 1556 (including patients from excluded arm).
Adverse events (AEs) of chloroquine (CQ) were defined as AEs reported during the chloroquine treatment.
The AEs seen were:
• itching (5),• burning of palms (1),• abdominal pain (1),• loose motion (1),• heat boils (1).
Of these 9 AEs, 1 AE of itching and mucous membrane on lips lead to discontinuation of CQ on D3.
AEs of primaquine (PQ) were defined as AEs that occurred after chloroquine treatment was completed. The
AEs seen were:
• nausea (1),• acidity (02),• weakness (1),• itching (09),• acidity plus itching (01),• abdominal pain (04),• acidity plus abdominal pain (01),• epigastric pain (02),• epigastric burning (01),• weakness plus abdominal pain (01),• vomiting (01),• mucocutaneous lesions on leR leg and gluteal region (01),• boils on forehead and back with pus (01),• boils rash-maculopapular-all over body (01),• swelling of upper lips, legs, and palms with itching (01),• severe pruritus (01),• morbilliform rash in fingers (01),• boils inside the mouth and tongue (01).
 
 
2 0.5 mg/kg/day for 7 days versus standard 14-day regimen
 
Study 0.5 mg/kg/day for 7 days Standard 14-day regimen
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Abdon 2001 BRA Total population = 23 patients (including participants from excluded arm); 19.2% experienced AEs, these in-
cluded:
• diarrhoea (5.8%)• nausea (5%)• itching (5%)• vomiting (1.7%)• epigastric pain (1.7%)• dizziness (0.8%)• tinnitus (0.8%)
Pareek 2015 IND AEs during PQ administration and subsequent fol-
low-up
• Total events: 11/120• Total N of patients with AEs: 6/120
• Malaise: 1• Headache: 2• Nausea: 1• Decreased appetite: 0• Pyrexia: 1• Vomiting: 1• Dizziness: 1• Myalgia: 0• Asthenia: 1• Arthralgia: 0• Pruritus: 1• Haemoglobin decreased: 1• Muscle spasms: 0• Dyspnoea exertional: 0• Dyspepsia: 1• Diarrhoea: 0• Diarrhoea: 0• Cough: 0
None of the patients from primaquine SR 30mg
group showed
intolerance or dose-related side effects.
AEs during PQ administration and subsequent fol-
low-up
• Total events: 10/120• Total N of patients with AEs: 5/120
• Malaise: 3• Headache: 1• Nausea: 2• Decreased appetite: 0• Pyrexia: 1• Vomiting:1• Dizziness: 0• Myalgia: 2• Asthenia: 0• Arthralgia: 0• Pruritus: 0• Haemoglobin decreased: 0• Muscle spasms: 0• Dyspnoea exertional: 0• Dyspepsia: 0• Diarrhoea: 0• Diarrhoea: 0• Cough: 0
Rajgor 2014 IND Total population = 1556 (including patients from excluded arm).
AEs of chloroquine were defined as AEs reported during the chloroquine treatment. The AEs seen were:
• itching (5),• burning of palms (1),• abdominal pain (1),• loose motion (1),• heat boils (1).
Of these 9 AEs, 1 AE of itching and mucous membrane on lips lead to discontinuation of CQ on D3.
AEs of primaquine were defined as AEs that occurred after chloroquine treatment was completed. The AEs
seen were:
• nausea (1),
  (Continued)
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• acidity (02),• weakness (1),• itching (09),• acidity plus itching (01),• abdominal pain (04),• acidity plus abdominal pain (01),• epigastric pain (02),• epigastric burning (01),• weakness plus abdominal pain (01),• vomiting (01),• mucocutaneous lesions on leR leg and gluteal region (01),• boils on forehead and back with pus (01),• boils rash-maculopapular-all over body (01),• swelling of upper lips, legs, and palms with itching (01),• severe pruritus (01),• morbilliform rash in fingers (01),• boils inside the mouth and tongue (01)
  (Continued)
 
1 mg/kg/day for 7 days versus high-standard 14-day regimen
 
Study 1 mg/kg/day for 7 days high-standard 14-day regimen
AEs leading to discontinuation of treatment by blood-stage
antimalarial treatment:
• chloroquine group: 1/165• DHA-PPQ group: 2/162
AEs leading to discontinuation of treatment
by blood-stage antimalarial treatment:
• chloroquine group: 0/164• DHA-PPQ: 1/163
Anaemia or change in haemoglobin status
• chloroquine group: 12/165• DHA-PPQ group: 20/162
Anaemia or change in haemoglobin status
• chloroquine group: 17/165• DHA-PPQ group: 18/162
Chu 2019 THA
Other adverse events
• Abdominal pain* chloroquine group: 44/165* DHA-PPQ group: 25/162• Nausea or vomiting* chloroquine group: 12/165* DHA-PPQ group: 5/162• Dizziness* chloroquine group: 15/165* DHA-PPQ group: 18/162• Headache* chloroquine group: 15/165* DHA-PPQ group: 18/162• Fatigue* chloroquine group: 11/165* DHA-PPQ group: 6/162
Other adverse events
• Abdominal pain* chloroquine group: 35/164* DHA-PPQ group: 13/163• Nausea or vomiting* chloroquine group: 10/164* DHA-PPQ group: 9/163• Dizziness* chloroquine group: 22/164* DHA-PPQ group: 29/163• Headache* chloroquine group: 15/164* DHA-PPQ group: 21/163• Fatigue* chloroquine group: 9/164* DHA-PPQ group: 10/163
Taylor 2019 MULTI Serious adverse events Serious adverse events
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• Primaquine-related, up to 42 days follow-up: 9/935• Primaquine-unrelated, up to 42 days follow-up: 3/935• Primaquine-related, up to 1 year follow-up: 9/935• Primaquine-unrelated, up to 1 year follow-up: 9/935
Related events include those that are possibly, probably or
definitely related
• Primaquine-related, up to 42 days fol-
low-up: 1/937• Primaquine-unrelated, up to 42 days fol-
low-up: 0/937• Primaquine-related, up to 1 year follow-up:
1/937• Primaquine-unrelated, up to 1 year fol-
low-up: 4/937
Related events include those that are possi-
bly, probably or definitely related
SAE details
Up to 42 days
• Persistent vomiting – 2 days after treatment (possibly re-
lated)• Acute haemolysis (Hb drop from 13.7 to 9.5 g/dL) – 3 days
after treatment (definitely related)• Haemolysis (Hb drop from 11.6 to 6.9 g/dL) – 3 days after
treatment (possibly related)• Epigastric pain – 4 days after treatment (possibly related)• Persistent vomiting – 4 days after treatment (probably re-
lated)• Acute haemolysis (Hb drop from 15.3 to 6.4 g/dL) – 5 days
after treatment (definitely related)• Diarrhoea – 7 days after treatment (definitely related)• Fever, abdominal pain, dyspnoea – 9 days after treatment
(possibly related)• Symptomatic methaemoglobinaemia and bronchopneu-
monia – 10 days after treatment (definitely related)• Severe malaria (P falciparum + P vivax) – 2 days after treat-
ment (not related)• Abdominal pain, fever of unexplained origin – 6 days after
treatment (not related)• Persistent vomiting – 10 days after treatment (not relat-
ed)
42 days to 1 year
• Severe P falciparum malaria – 46 days after treatment
(not related)• Unilateral periorbital ecchymosis – 54 days after treat-
ment (not related)• Severe P falciparum malaria – 57 days after treatment
(not related)• Sudden unexpected death due to myocardial infarction –
151 days after treatment (not related)• Acute appendicitis – 170 days after treatment• Severe P falciparum malaria – 221 days after treatment
(not related)
SAE details
Up to 42 days
• Haemolysis (Hb drop from 10.2 to 6.8/dL) –
3 days after treatment (probably related)
42 days to 1 year
• Acute exacerbation of bronchial asthma
precipitated by pneumonia – 91 days after
treatment (not related)• Generalized peritonitis – 92 days after treat-
ment (not related)• Complicated puncture wound – 129 days
after treatment (not related)• Undifferentiated carcinoma in nasophar-
ynx – 147 days after treatment (not related)
• Mean (SD) absolute decrease in haemoglobin at day 3, g/
dL = 0.52 (1.19)• Mean (SD) absolute decrease in haemoglobin at day 7, g/
dL = 0.01 (1.23)
• Mean (SD) absolute decrease in haemoglo-
bin at day 3, g/dL = 0.62 (1.09)• Mean (SD) absolute decrease in haemoglo-
bin at day 7, g/dL = 0.12 (1.09)
  (Continued)
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Symptoms elicited from daily questionnaires, 1–14 days af-
ter starting antimalarial treatment
• Headache: 480/935• Diarrhoea: 95/935• Skin rash: 22/935• Poor appetite: 407/935• Myalgia or arthralgia: 243/935• Fever: 294/935• Passing dark urine: 55/935• Dizziness: 166/935• Shortness of breath: 33/935• Itching: 24/935
Symptoms elicited from daily questionnaires,
1–14 days after starting antimalarial treat-
ment
• Headache: 465/937• Diarrhoea: 52/937• Skin rash: 26/937• Poor appetite: 374/937• Myalgia or arthralgia: 236/937• Fever: 319/937• Passing dark urine: 48/937• Dizziness: 157/937• Shortness of breath: 29/937• Itching: 26/937
  (Continued)
 
Appendix 3. Primary outcomes additional analyses
3a. Rate ratios and hazard ratios for the outcome ‘Recurrence’ at 12 months follow-up of the comparison ‘1.0 mg/kg/day
primaquine for 7 days versus high-standard 14-day regimen’
 
Subgroup Study Events/per-
son-yearsa
Rate ratio (95%
CI)
Pooled
rate ratio
(95% CI)b
HR (95% CI)c
Chu 2019
THA
PQ7: 20/128
PQ14: 26/125
0.72 (0.28 to 1.90) -Blood-stage drug:
chloroquine
Taylor 2019
MULTI
PQ7: 54/286
PQ14: 55/303
1.04 (0.71 to 1.51)
Subtotal:
0.99 (0.70
to 1.40)
-
Chu 2019
THA
PQ7: 17/114
PQ14: 16/122
1.14 (0.57 to 2.25) -Blood-stage drug:
DHA-PPQ
Taylor 2019
MULTI
PQ7: 44/311
PQ14: 33/312
1.34 (0.85 to 2.10)
Subtotal:
1.27 (0.87
to 1.85)
-
See Analysis 4.1 for risk ratio. Total: 1.11
(0.86 to
1.44)
Total HR reported in Taylor 2019
MULTI: 1.17 (0.88 to 1.55)
Geographical re-
gion: Afghanistan
Taylor 2019
MULTI
PQ7: 20/74
PQ14: 27/78
0.78 (0.44 to 1.40)   Jalalabad: 0.74 (0.30 to 1.84)
Laghman: 0.90 (0.44 to 1.83)
Geographical re-
gion: Ethiopia
Taylor 2019
MULTI
PQ7: 25/124
PQ14: 19/135
1.42 (0.78 to 2.58)   Arba Minch: 1.54 (0.79 to 2.98)
Metahara: 1.08 (0.35 to 3.34)
Geographical re-
gion: Indonesia
Taylor 2019
MULTI
PQ7: 44/311
PQ14: 33/312
1.34 (0.85 to 2.10)   Hanura: 1.16 (0.71 to 1.90)
 
Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax (Review)
Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
82
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Tanjung Leidong: 2.36 (0.83 to
6.69)
Geographical re-
gion: Thailand
Chu 2019
THA
PQ7: 37/242
PQ14:42/247
0.90 (0.58 to 1.40)   -
Geographical re-
gion: Vietnam
Taylor 2019
MULTI
PQ7: 9/89
PQ14:9/91
1.03 (0.41 to 2.58)   Dak O & Bu Gia Map: 1.21 (0.49 to
2.97)
Krong Pa: 0.47 (0.04 to 5.18)
See Analysis 4.2 for risk ratio. Total: 1.07
(0.84 to
1.37)
Total HR: 1.17 (0.88 to 1.55)
  (Continued)
 
aEvents/person-years (or per person-days converted to person-years) reported in study reports for estimation of rate ratios.
bPooled rate ratios were calculated in RevMan 5 (analyses not shown) based on log rate ratios and their SEs using the generic inverse
variance method.
cHazard ratios reported by study site in Taylor 2019 MULTI.
3b. Rate ratios for the outcome ‘Recurrence’ at 3 and 6 months follow-up of the comparison ‘1.0 mg/kg/day primaquine for 7 days
versus high-standard 14-day regimen’
 
Study Follow-up Subgroup Events / person-years Rate ratio (95% CI)
Blood-stage drug: chloroquine PQ7: 35/122
PQ14: 27/128
1.36 (0.82 to 2.25)Taylor 2019
MULTI
3 months
Blood-stage drug: DHA-PPQ PQ7: 7/98
PQ14: 5/96
1.37 (0.44 to 4.32)
See Analysis 4.3 and Analysis 4.4 for risk ratios   Total: 1.36 (0.86 to 2.16)
Blood-stage drug: chloroquine PQ7: 53/231
PQ14: 51/245
1.10 (0.75 to 1.62)Taylor 2019
MULTI
6 months
Blood-stage drug: DHA-PPQ PQ7: 32/193
PQ14: 19/189
1.65 (0.94 to 2.91)
See Analysis 4.3 and Analysis 4.4 for risk ratios   Total 1.25 (0.91 to 1.72)
 
 
W H A T ' S   N E W
 
Date Event Description
7 July 2020 New citation required and conclusions
have changed
We included two new large important trials using higher dose
for 7 days compared to high standard 14-day course, following a
search update to 2 September 2019.
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Date Event Description
7 July 2020 New search has been performed We updated the date of search to 2 September 2019.
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